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ADP-ribosylation is a post-translational modification synthesized by poly(ADP-ribose) polymerases 
(PARPs) and is the target of the chemotherapeutic PARP inhibitors. This protein modification has 
proven clinically important in DNA damage repair, inflammatory processes and cell death, and 
biologically important in nearly all cellular processes. Research into ADP-ribosylation has been 
limited, however, by a lack of mass spectrometry (MS) based methods for identifying protein 
modification sites. My thesis work has provided a robust, unbiased method for identifying ADP-
ribosylation sites by simplifying this otherwise complex modification down to its phosphoribose 
attachment site, a 212 Dalton molecule which is easily identifiable by MS and can be enriched using 
standard phosphoenrichment matrices. Through the development and validation of this assay we (1) 
identified the automodification sites on PARP-1, a critical protein for DNA repair, among other 
cellular processes, (2) identified the ADP-ribosylation sites on endogenous proteins, (3) showed that 
the macrodomain containing protein MacroD2 has ADPr hydrolase activity, and (4) found that 
Nudix enzymes, otherwise known for degrading free ADPr into phosphoribose and AMP, are 
capable of degrading protein-conjugated poly- and mono(ADP-ribose). This thesis also contains a 
chapter dedicated to benchmarking the current state of the ADP-ribosylation field with regard to MS 
based proteomics, and considerations for the future promise and potential held by MS based 
proteomics for the study of ADP-ribosylation. 
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 Post-translational modifications (PTMs) regulate the stability [1], localization [2] and 
interaction networks [3] of cellular proteins in a dynamic and reversible fashion, expanding upon the 
baseline number of protein effectors in the cell through the creation of protein proteoforms (variable 
molecular forms of a single gene product [4]). The study of PTMs has been bolstered by the advent 
of mass spectrometry based proteomics, wherein proteins are digested into approximately 20 amino 
acid long peptides which can then be identified through fragmentation and determination of the 
mass-to-charge ratio of these fragments (see Figure 1-1). Recent advances in both the technology for 
rapidly and accurately sampling increasingly complex mixtures of peptides as well as the analytical 
software required to process, validate, and explore these datasets have allowed mass spectrometry 
based proteomics to become the gold standard for global PTM research [5]. The work presented in 
this thesis aims to develop mass spectrometry based proteomic tools for the study of protein ADP-
ribosylation. 
1.1 PARPs and ADP-ribosylation: clinically and biologically important 
 Protein ADP-ribosylation (poly(ADP-ribosyl)ation/PARylation and mono(ADP-
ribosyl)ation/MARylation) is a protein modification synthesized by ADP-ribosyltransferases 
(commonly known, and hereafter referred to, as Poly(ADP-ribose) Polymerases, or PARPs) which 
transfer the ADP-ribose (ADPr) group from NAD+ (Nicotinamide Adenine Dinucleotide) onto 
acceptor proteins or, in the case of PAR, existent ADP-ribosylation sites (thus forming polymers) 
(see Figure 1-2). The PARP family is made up of 17 proteins that contain the characteristic PARP 
domain, of which four (PARP-1, -2, -5a and -5b) are capable of synthesizing PAR, two (PARP-9 and 
-13) have no known ADP-ribosylation activity, one (PARP-4) can synthesize MAR or PAR, with the 
remaining enzymes responsible for MARylation (PARP-3, -6, -7, -8, -10, -11, -12, -14, -15, 16) (see 
[6], Table 1-1 and Figure 4-1).  
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1.1.1 PARPs and DNA repair 
 The PARP field has emerged directly from the field of DNA repair, and it is in this context 
that basic discovery and research ultimately yielded a new class of chemotherapeutic drugs for 
patients battling ovarian cancer (later), as well as a deeper understanding of cellular roles affected by 
this superfamily of enzymes. It began in 1963 when PARP1 was first described as a DNA-dependent 
polymerase: Chambon et al  noted that nicotinamide mononucleotide (NMN, the precursor to 
NAD+) stimulated PARP1 to produce a polyA-like product in the presence of DNA [7]. This 
polymer was identified as poly(ADP-ribose) (and the precursor correctly identified as NAD+, 
referred to as DPN or Diphosphopyridine nucleotide) three years later [8] and in 1980 Benjamin and 
Gill noted that damaged DNA, not specific DNA sequences, were responsible for activating PARP1 
[9]. By the early 1990s the now steadily growing field knew that the NAD+-dependent 
automodification of PARP1, along with degradation of PAR by the poly(ADP-ribose) glycohydrolase 
PARG, is critical for repair of DNA single-stranded as well as double-stranded breaks in human cells 
[10]. The physiological impact of this basic research was validated from 1995-1998 through the 
creation of three independent PARP1-/- mouse models, all of which proved highly sensitive to DNA 
alkylating agents and ionizing radiation [11-13]; MEF cells derived from these mice demonstrated 
sensitivity to methyl methanesulfonate (MMS, an alkylating agent and carcinogen), resulting in slower 
cell growth and chromosomal instability [14]. Creation of these mice also lead to the discovery of 
PARP2, as PARP1-/- MEFs were found capable of producing PAR upon stimulation with the 
alkylating agent MNNG [15, 16]. In 2003 a PARP2 deficient mouse model also demonstrated 
sensitivity to DNA alkylating agents, implicating PARP2 in DNA repair, and a PARP1-/-PARP2-/- 
mouse model was embryonic lethal, suggesting the two enzymes are otherwise compensating for 
each other in critical cellular processes [17]. During this same time period PARP1 was found to 
interact with XRCC1 in Saccharomyces cerevisiae, suggesting its role in the single stranded break repair 
pathway known as base excision repair (BER) [18], a suggestion which was confirmed in 2003 by two 
separate studies which showed that PARP1 is responsible for the accumulation of XRCC1 at sites of 
DNA damage [19, 20], at the same time that Schreiber et al showed that PARP2 is also involved in 
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BER [21]. PARP1 would not be mechanistically linked to double stranded DNA break repair until 
2006, when it was shown that PARP1 binds to double stranded breaks and competes with the NHEJ 
initiation factor Ku to stimulate alternative NHEJ [22] (also known as microhomology-mediated end 
joining, MMEJ). 
 Acknowledgement of PARP1’s critical role in BER led to the proposal that a loss or 
inhibition of PARP1 (and thus BER) should be synthetically lethal in cells which are missing the high 
fidelity double stranded break repair pathway homologous recombination (HR) (see Figure 1-3): loss 
of BER would lead to an accumulation of single stranded DNA breaks which would collapse into 
double stranded DNA breaks and be repaired by the low-fidelity pathway NHEJ (which would also 
be spurred on by a lack of PARP1, see previous paragraph) instead of the unavailable high-fidelity 
HR. An important scenario where this could occur is in cells lacking functional BRCA genes, as 
BRCA1 and BRCA2 are necessary for HR [23]. In 2005 two Nature papers showed the power of this 
synthetically lethal approach: cells carrying mutant BRCA1 or BRCA2 are highly sensitized to PARP 
inhibition [24, 25]. These findings propelled PARP inhibitors into the clinical spotlight and brought 
on a decade of intense clinical trials which resulted in the FDA approval of the PARP inhibitor 
olaparib for the treatment of ovarian cancer in patients carrying BRCA mutations ([26] and Figure 
1-4). 
 A number of other PARPs have recently been linked to genome integrity: PARPs 5a and 5b 
play critical roles at telomeres (see section 1.1.3), PARP3 was recently shown to be recruited to laser-
induced sites of DNA damage where it acts as part of the non-homologous end joining (NHEJ) 
pathway [27, 28], PARP9 is recruited by PARP1 to sites of double stranded DNA breaks via its PAR 
binding macrodomain [29], PARP10 binds to PCNA and is important for its DNA repair activity 
during S-phase, potentially through its MARylation of PCNA [30], and PARP14 assists in 
homologous recombination [31]. PARPs and ADP-ribosylation, then, are critically important in 
nearly all means of repairing damaged DNA, a role which firmly ties them to cell viability and the 
development and treatment of cancer. 
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1.1.2 PARPs and transcription 
 The idea that PAR can directly affect transcription was first proposed by Poirier et al in 1982, 
in which they showed that PARylated polynucleosomes are more ‘relaxed’ than their unmodified 
counterparts, presumably due to the electrostatic repulsion that exists between negatively charged 
polymers of DNA and PAR [32]. That same year Zahradka and Ebisuzaki expanded this notion by 
showing that PARP1 and PARG coordinate their activities to shuttle PARP1 on and off of DNA, 
likely opening and closing chromatin as a result [33]. While the aforementioned research teams were 
focused on characterizing PARP1 in transcription, Slattery et al was working to identify a 
transcription factor from HeLa cells which they knew was capable of blocking ‘random’ transcription 
(i.e. that induced by DNA nicking as opposed to promoter-induced transcription) by RNA Pol II, 
their isolation and characterization of this enzyme (which they had named TFIIC) revealed it to be 
PARP1, leading to their hypothesis that PARP1 binds nicked DNA with higher affinity than Pol II, 
competing it off of the DNA and preventing noisy transcription [34]. Thus, in less than a year, 
PARP1 became a bona fide transcriptional regulator, four years before the PARP1 gene would even be 
cloned [35, 36]. The free PAR polymer was shown to be a potential transcription mediator on its 
own in 1992: Panzeter et al isolated the polymer and proved that PAR binds noncovalently to all of 
the histones in a detergent and high-salt resistant manner but the binding is easily reversed by DNA, 
suggesting an elegant competitive regulation between PAR and DNA in the cell [37]. 
 The 1990s also revealed PARP1 to be both a transcription factor (of its own expression 
[38]), and a regulator of transcription factors, with the seminal discovery that PARP1 interacts 
directly with the ubiquitous transcription factor Yin Yang 1 (YY1) [39]. This regulation of 
transcription factors predictably extended to include the PARylation of transcription factors as a 
means for regulating their interaction with DNA, as was discovered for the PARylation of the 
TATA-binding protein and RNA Pol II, preventing their binding to DNA, potentially preventing 
them from binding and transcribing a damaged gene that is undergoing repair [40, 41]. In 2001 it was 
discovered that PARP1 is responsible for the expression of Reg protein (a gene which induces beta-
5 
  
cell replication and is important in diabetes progression) through its interaction with a cis-element in 
the Reg gene promoter -- PARP1 automodification abolishes this interaction and thus prevents 
expression of Reg [42]. The extent of PARP1’s regulatory power as a transcription factor is 
epitomized by its repression and activation of neural gene MASH1, repression when unstimulated 
but activation when phosphorylated and thus enzymatically active [43]. 
 The PARylation dependent relaxation of chromatin, as proposed by Poirier et al in 1982 [32], 
was put into physiological context in 2003 when Tulin and Spradling showed that Drosophila PARP 
is required for chromosomal loosening (puffing) in response to heat shock [44], a concept which was 
extended by Kim et al who showed that PARP1’s zinc fingers bind to the DNA entering and exiting 
nucleosomes, competing with the linker histone to variable extents depending on its auto-PARylation 
status. This replacement of Histone H1 allows for a slightly less condensed chromatin formation, but 
is still distinct from the open, transcriptionally active chromatin and is presumably subject to PAR-
dependent regulation [45]. Between 2008 and 2012 Petesch and Lis showed that PARP1 is necessary 
for heat shock induced nucleosome loss at the Hsp70 promoter in Drosophila melanogaster [46], and 
that PARP1 activity is required in this scenario as PARP1 spreads along the DNA, removing 
nucleosomes and leaving PAR in its wake [47]. 
 The last decade has revealed that knockdown of PARP2 affects the activity of transcription 
factors directly, including thyroid transcription factor 1 [48] and the heterodimeric RXR/PPARγ 
nuclear receptor [49], and indirectly such as through the repression of the transcription factor 
regulatory protein Sirt1 [50]. PARP2 also affects transcription through its regulation of 
Topoisomerases, enzymes that assist in transcription by managing the supercoiling introduced into 
DNA when strands are separated. Both PARP1 and PARP2 are known to reactivate Topoisomerase 
I by removing it from nicked DNA [51] and inactivate Topoisomerase β [52], suggesting a complex 
regulatory role in chromatin condensation. 
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1.1.3 PARPs and Mitosis 
 Mitosis in eukaryotes requires proper formation of the mitotic spindle apparatus (depicted in 
Figure 1-5), a structure made up of chromosomes and two proteinaceous centrosomes [53]. PARPs 
have been localized to the telomeres and centromeres of chromosomes as well as at the centrosomes, 
an organelle that serves as the microtubule organizing center at the poles of the mitotic spindle. 
1.1.3.1 PARPs at Telomeres 
 At the end of the 20th century Susan Smith et al identified PARP5a (tankyrase 1) as a novel 
member of the PARP family capable of both PARylation activity and regulation of the telomere-
protecting shelterin complex [54]. Specifically, PARP5a interacts with TRF1 (one of two telomere-
binding proteins in the six-protein shelterin complex) through its ankyrin repeats and then PARylates 
it, resulting in the release of TRF1 from telomeres. In 2002 PARP5b (tankyrase 2) was also found to 
PARylate and release TRF1 from telomeres [55], and two years later Dynek and Smith showed that 
knockdown of PARP5a results in mitotic arrest and abnormal chromosomal separation due to a 
failure of the telomeres to fully resolve [56]. More recently, Donigian et al showed that knockdown of 
PARP5a results in a shortening of telomeres in a dose-dependent manner, and this shortening is due 
to retention of Trf1 (and thus shelterin) at the telomeres, suggesting that PARP5a allows elongation 
of telomeres through removal of Trf1. They also show that this pathway is absent in mice due to the 
absence of a tankyrase binding domain in mouse Trf1 [57]. PARP1 and PARP2 are also at telomeres 
where they bind TRF2 (the other telomere binding protein from the shelterin complex) and 
PARylate it, thus preventing it from binding telomeres [58, 59]. PARPs, then, are highly responsible 
for the localization of shelterin to human telomeres, and ultimately the length of these critical 
stretches of DNA. 
1.1.3.2 PARPs at Centromeres: 
 Centromeres are found at the attachment site of sister chromatids and present a binding site 
for the kinetochore, a structure which links chromosomes to the spindle assembly and mediates 
proper separation of genomic material during mitosis. PARP1 was first found to localize to these 
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centromeres in 2000 [60], shortly followed by the identification of PARP2 at the centromeres 
(though their localization is not fully overlapped, PARP1 is a more diffuse pattern, PARP2 is more of 
a double banding pattern) and the recognition that both PARP1 and PARP2 are interacting with and 
PARylating the constitutive centromeric components CENPA and CENPB as well as the spindle 
assembly checkpoint protein BUB3 [61, 62]. The idea that PARP1 and PARP2 have slightly different 
roles at the centromeres is supported by their respective mouse models: PARP1-/- mice show 
apparently normal centromere function and progression through mitosis [63] while PARP2-/- mice 
have chromosomal mis-segregation due to kinetochore defects [17]. While the role of PARP2 at 
centromeres has remained understudied, PARP1 has been shown to assist in the integration of HIV-
1 into centromeric DNA [64] and has proven to be required in mouse oocytes for recruitment of 
Bub3 to the centromere [65]. 
1.1.3.3 PARPs at the Centrosome 
 The centrosome powers and regulates the segregation and alignment of chromosomes at the 
metaphase plate during eukaryotic cell division [53]. In 1999 it was found that both PARP5a [66] and 
PARP4 [67] localize to mitotic centrosomes, followed quickly by the finding that PARP3 is a core 
component of the centrosome (it specifically localizes to the daughter centriole) and interferes with 
G1/S cell cycle progression, briefly interacting with PARP1 [68]. The potential impact of these new 
centrosome components was revealed in 2004 when Chang et al showed that PAR is enriched in both 
Xenopus and vertebrate spindles and required for proper spindle assembly [69] and Dynek and Smith 
noticed an aberrant (fat and/or misaligned) spindle morphology following knockdown of PARP5a 
[56]. In 2005 both of these groups definitively showed that PARP5a is required for successful cell 
division and that it is responsible for PARylating the spindle-pole organizing protein NuMA [70, 71]. 
In 2013 Vyas et al showed that six PARPs localized to the centrosomes: PARP2 and PARP3 in 
G0/G1, PARP11 and PARP5b during mitosis and PARP5a and PARP8 constitutively (they did not 
see PARP1 and PARP4, as had been previously reported) [72].  The role of these newly identified 
centrosome-localized PARPs has yet to be revealed. 
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1.1.4 PARPs in RNA regulation 
1.1.4.1 PARylation in cytoplasmic nucleoprotein granules (stress granules) 
 The existence of cytoplasmic PAR has been known since the mid-1970s when Roberts et al 
localized it to the ribosomes as well as diffusely to the rest of the cytoplasm [73]. A few years later (5 
years before PARP1 cDNA would be cloned, 15 years before PARP2 would be discovered) Elkaim et 
al published their landmark paper linking cytoplasmic RNA to mRNPs (mRNA nucleoprotein 
particles) and correctly proposing that the PARylation activity observed in these macromolecular 
complexes was distinct from the nuclear PARylation activity thus observed; it was stimulated by 
RNAse degradation of the local RNAs, as opposed to DNA [74]. The authors also identified a 
number of PARylated mRNP proteins and showed that addition of snake venom phosphodiesterase 
(and thus degradation of PAR) caused the granules to become partially acid soluble, suggesting that 
PAR is a structural component of these particles [74, 75]. In 2011 Leung et al identified these 
cytoplasmic granules as stress granules and showed that PAR, two isoforms of PARG, and 6 
different PARPs (5a, 12, 13.1, 13.2, 14 and 15), are localized to these granules, some of these PARPs 
regulate microRNA activity and PARylate Ago2, Poly(A)-binding protein, TIA1, and G3BP1 [76]. 
1.1.4.2 ADP-ribsoylation of RNA regulatory proteins 
 By the early 1980s the field knew that HNRNPs are major PAR acceptors [77] (HNRNPs 
A1 & A2 would be confirmed as the major acceptors of MAR and PAR in HeLa cells in 1994 [78]) 
and that ADP-ribosylation of eukaryotic elongation factor 2 (EF-2) by diphtheria toxin leads to loss 
of RNA binding by EF-2 and it’s detachment from polyribosomes [79]. The trend that proteins 
involved in the regulation of RNA are either interacting with PAR or are PARylated themselves was 
recently solidified by the advent of mass-spectrometry based studies which identified the ADP-
ribosylated interactome [80-83] as well as the ADP-ribosylated proteome [84, 85]; all of these studies 
identified a statistically significant population of RNA binding proteins [86]. This observation was 
solidified by a 2014 meta-analysis which showed a high correlation between RNA granule proteins 
and proteins that are known to be PARylated [87].  
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1.1.4.3 PARPs regulate viral RNA 
 Gao et al’s 2002 Science paper revealed that the catalytically inactive (unable to ADP-ribosylate 
proteins) PARP13 (termed ZAP) is responsible for removal of viral mRNAs from the cytoplasm of 
human cells [88]. The following year it was revealed that cells expressing PARP13 are protected from 
infection by four different alphaviruses (positive-sense single stranded RNA viruses) [89], and soon 
after that, that PARP13’s 2nd and 4th zinc fingers are responsible for this viral RNA binding [90]. 
More recently Zhu et al has found that PARP13 is able to inhibit HIV-1 infection by targeting its 
fully processed RNA for degradation [91]. Other PARPs have also been implemented in this viral 
resistance mechanism: PARP7 and PARP12 were found to inhibit alphavirus infection [92] and 
Atasheva et al showed that PARP7, PARP10 and PARP12 are all interferon stimulated and prevent 
alphavirus infection through downregulation of viral translation [93]. 
1.1.5 PARPs and cell death 
 In the simplest of terms, apoptosis is cellular death triggered internally (and is considered a 
normal, healthy, and controlled form) while necrosis is triggered externally and is often uncontrolled 
and harmful, resulting in the release of intracellular contents and the activation of inflammatory 
responses. Parthanatos has been established as a separate cellular death response that is uniquely 
dependent upon mitochondria and poly(ADP-ribose). PAR and PARPs, however, are involved in all 
three subtypes. 
1.1.5.1 Apoptosis 
 Apoptosis is a controlled form of cell death that is energy intensive, therefore one of the 
earliest steps in this pathway is to prevent the consumption of the energetically important coenzyme 
NAD+ by PARP1 through caspase-mediated cleavage of PARP1[94], a process first observed in 1993 
[95] that explained the Berger hypothesis of cell death from 1985 [96]. This cleavage event has 
proven to be critical for preventing necrosis, as cells expressing an uncleavable form of PARP1 have 
an increased rate of necrotic cell death [97-99]. PARP5a has also been strongly tied to apoptosis, 
originally though its interaction with and regulation of the apoptosis inducing and suppressing Mcl-1 
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proteins [100] and more recently through independent demonstrations that PARP5a inhibition or 
silencing induces apoptosis in human lung cells [101], neuroblastomal cells [102], and osteosarcoma 
cell lines [103]. 
1.1.5.2 Necrosis 
The most obvious link between PARPs and necrosis is through the energy intensive 
synthesis of poly(ADP-ribose), a polymer made from the energetically important molecule NAD+. In 
1983 it was noted that inhibition of PARPs prevents energy depletion in dying cells [104] and in the 
1990s it was shown that PARP1 activation (through DNA damage) causes necrosis in pancreatic islet 
cells [105], neuronal cells [106] and fibroblasts [107], all of which can be reversed by loss or 
inhibition of PARP1. PARP1 also plays roles in necrosis beyond the depletion of NAD+ and ATP 
[107, 108]: PARP1 PARylates HMGB1 (high mobility group 1 protein), leading to its subsequent 
acetylation, detachment from chromatin, and translocation to the cytoplasm where it is released upon 
necrosis, triggering inflammation [109, 110]. PARP5b has also been shown to initiate caspase-
independent necrosis, a phenomenon that is reversed through inhibition of PARP5 activity [111]. 
1.1.5.3 Parthanatos 
Parthanatos, or PAR-dependent cell death, has recently been considered a form of regulated 
necrosis [112] as it is based on regulated molecular pathways while still producing a necrotic 
outcome. Specifically, it was discovered in 2002 that PARP1 activation leads to the translocation of 
AIF (Apoptosis Inducing Factor) from the mitochondria to the nucleus, thus initiating caspase-
independent cell death, termed parthanatos [113] (see Figure 1-6). This process is specifically 
dependent upon the PAR polymers as a signal, as PAR polymers (especially long, complex polymers) 
signal for AIF release from the mitochondria [114] and AIF must bind these polymers directly for 
parthanatos to occur [115]. Molecular inhibition of parthanatos was discovered in 2011 when Iduna, 
a PAR binding protein, was found to protect against parthanatos in neural cells [116]. 
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1.1.6 PARPs and inflammatory signaling 
The important connection between PARPs and inflammatory signaling was first suggested in 
1995 when a PARP inhibitor was found to suppress immune responses in murine spleen cells [117]. 
Today the immunomodulatory effects of PARP inhibitors are far from understood, but two major 
interaction networks have come into focus: the immunostimulatory effect of PARP1 through NF-κB 
signaling, and the immunosuppressive effect of PARP14 through Stat6/IL-4 signaling. 
1.1.6.1 Pro-inflammatory signaling through PARP1 mediated regulation of NF-κB 
PARP1 was found to modulate NF-κB signaling in 1999 when Oliver et al noticed that 
PARP1-/- cells are deficient in NF-κB dependent transcriptional activation in LPS treated 
macrophages [118] at the same time that Hassa and Hottiger showed that PARP1 and NF-κB interact 
independent of DNA binding and that this interaction was important for NF-κB activation [119]. It 
wasn’t until a decade later that the complexity of this regulation became clear: on the one hand, DNA 
damage induces PARP1 to PARylate Iκκγ (NEMO), an inhibitor of NF-κB activity, leading to its 
ubiquitination and subsequent degradation of Iκκγ, thus promoting NF-κB activity [120, 121], on the 
other hand, extracellular (TLR4) signaling causes PARP1 to PARylate  p65 NF-ĸB, regulating its 
export and nuclear retention following TLR4 stimulation [122]. These unique means of PARP1 
mediated NF-κB activation were validated in 2011 when Hunter et al showed that PARP1’s catalytic 
activity is required for the activation of NF-κB following ionizing radiation but not following TNF-α 
signaling [123]. PARP1’s close relationship with NF-κB activity in multiple settings makes it a critical 
player in inflammatory signaling. 
1.1.6.2 Anti-inflammatory signaling through PARP14 mediated regulation of Stat6 
In 2007 PARP14 was identified by Goenka et al as CoaSt6 (co-activator of Stat6), which they 
showed to activate the immunomodulatory transcriptional factor Stat6 [124]. This mechanism was 
fleshed out by Mehrotra et al in 2011 when they discovered that PARP14 acts a molecular switch for 
Stat6: when cells are quiescent PARP14 recruits HDAC2 and 3 to IL-4 responsive promoters, 
silencing them. Upon IL-4 stimulation PARP14 recruits Stat6 and releases HDAC2 and 3 by 
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MARylating them, following which HATs occupy and activate the promoters [125]. PARP14’s ADP-
ribosylation activity, then, serves to inhibit inflammatory signaling, in contrast to the PARP1 
dependent regulation of NF-κB. This balance must be considered in the use of family-wide PARP 
inhibitors for the study or treatment of inflammation.  
1.1.7 The therapeutic inhibition of PARPs 
 The PARP family is perhaps best known as a chemotherapeutic target for PARP inhibitors, a 
class of drugs propelled into the spotlight 10 years ago when it was shown that inhibition of PARP 
activity (and thus repair of DNA single stranded breaks via base excision repair) is a powerful 
‘second hit’ against cancer cells carrying BRCA1 or 2 (collectively BRCA) mutations (which are 
defective in DNA double stranded break repair by homologous recombination) [24, 25] (see Section 
1.1.1, Figure 1-3 and Figure 1-4). This synthetic lethality of PARP1 and BRCA loss has proven a 
successful therapy for ovarian cancer patients, with the first FDA approved PARP inhibitor, olaparib, 
hitting the clinic this year [26]. The potential for PARP inhibitors extends further, however, as PARP 
plays a more complex role in DNA damage repair than just initiation of base excision repair [126]. 
Furthermore, PARPs are important regulators of cell death and inflammation, processes dysregulated 
in most disease states. For these reasons clinical trials are ongoing for PARP inhibitors in a range of 
cancers (ovarian [127], breast[128], pancreatic, colorectal, gastric, lung, genitourinary, cervical, 
uterine, brain, head and neck, Ewing’s sarcoma, and melanoma are undergoing Phase II or III clinical 
trials [129]) as well as ‘alternative’ disease states, particularly neurodegenerative, neurotraumatic, and 
autoimmune disorders as well as following myocardial infarctions [130] (see Figure 1-7). With so 
much potential for real and meaningful therapeutic applications of PARP inhibitors, the study of 
PARP biology has been and will continue to be full speed and optimistic.  
1.2 Mass spectrometry based proteomics for the study of post-translational 
modification networks 
Network biology refers to the study of biological systems in the context of their interactions 
and larger molecular complexes as a means of connecting genotype and phenotype [131]. This way of 
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considering molecular pathways is an emerging and powerful exercise that requires large-scale, 
quantitative methods for studying the unique proteins (including their many post-translationally 
modified forms) that make up these networks. In this context there is a clear technological front-
runner: mass spectrometry (MS)-based proteomics. In its most established form, MS-based 
proteomics analyzes proteins from the ‘bottom up’ by digesting them down to short, 10-30 amino 
acid long, peptides which are then ionized before being injected into a mass analyzer where their 
mass-to-charge (m/z) ratio is determined before their ultimate demise in a detector which measures 
the number of ions (peptides) associated with that freshly determined m/z [132]. Targeted trapping 
(selection) of restricted m/z ratios (peptides), followed by fragmentation of these peptides, allows for 
peptide sequencing and determination of mass aberrations due to post-translational modifications 
(see Figure 1-1). It is this capability which sets LC-MS/MS (liquid chromatography separation prior 
to tandem mass spectrometry, as just described) apart from other means for identifying sites of post-
translational modifications – in a matter of seconds a single peptide can be isolated, fragmented, and 
(later) sequenced and identified, allowing a researcher to localize and quantify thousands of PTMs in 
a sample in a matter of days, if not hours [133]. When properly controlled, these global analyses can 
reveal changes in signaling pathways, potentially making important connections between molecular 
events and cellular outcomes [134]. The fields of protein phosphorylation [133], ubiquitination [135], 
acetylation [136] and glycosylation [137] have emerged as powerful players in cellular biology as a 
result of intensive, global MS-based proteomics analyses; judging from the collection of basic and 
clinical research presented in section 1.1 it seems likely that ADP-ribosylation may prove to be just as 
intriguing and critical of a protein modification following similar interrogation. 
1.3 Applying mass spectrometry based proteomics to the study of ADP-
ribosylation 
 As research in the clinic races ahead biochemists and cell biologists have strained to keep up 
with developing the necessary tools to assess and optimize the many PARP inhibitors and disease 
states being juggled in these trials. The tools, in fact, are quite limited: there is currently no antibody 
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to mono(ADP-ribose), leaving a large number of ADP-ribosylation events undetected by ELISAs 
and immunohistological screens, and the antibodies for poly(ADP-ribose) fail to distinguish between 
branched and linear forms, as well as length variants.  Furthermore, as this thesis work was beginning 
there were no proven mass spectrometry based methods for identifying ADP-ribosylation sites on 
endogenous proteins (for a comprehensive review, see chapter 4), a handicap which has surely 
restricted our understanding of the PARP inhibitors being used in clinical trials today. This need 
formed the basis of the work presented in this thesis, in which a mass spectrometry based proteomic 






Figure 1-1 A typical workflow for identifying protein sequences using ‘bottom-up’ LC-MS/MS 
Proteins of interest are digested to peptides through the use of proteases. These peptides are 
separated via liquid chromatography (LC), often based upon their hydrophobicity, and then ionized 
to ensure the peptides carry a charge. The mass (m), charge (z) and intensity of the peptides is 
determined by a mass spectrometer and displayed as intensity ‘peaks’ for each m/z ratio (MS1). An 
ion trap collects a distinct m/z ratio for fragmentation and again the m/z ratio and intensity are 
determined and displayed (MS2). Mass spectrometry analysis programs, along with expert validation, 
allows for the sequence of the peptide to be determined based on the masses of the fragmented 
(daughter) and intact (parent) peptide, these sequences can then be compared to protein databases to 
assign peptides to the proteins they are derived from. These analytical techniques also allow for the 





Figure 1-2 The structure of Poly(ADP-ribose) 
ADP-ribose subunits are derived from β-NAD+ and added onto proteins in a monomeric or 






Table 1-1 The PARP family 





Figure 1-3 Synthetic lethality explains the exquisite sensitivity to PARP inhibition observed in BRCA deficient 
cells 
PARP1 is involved in base excision repair (BER), a DNA repair process for single stranded breaks 
(SSBs); loss or inhibition of PARP1 prevents BER, thus leading to single stranded breaks 
deteriorating into double stranded breaks (DSBs), which are then repaired by either HR (homologous 
recombination) or NHEJ (non-homologous end joining). HR requires the breast cancer related 
proteins BRCA1 and BRCA2, if either of these proteins is mutated or missing HR cannot proceed, in 
which case cells are forced to rely on NHEJ, a low fidelity pathway that will ultimately lead to 
genomic catastrophe and death. This double-hit model is termed synthetic lethality. For more 




Figure 1-4 A historical view of the development of PARP inhibitors for cancer therapy. 
A sustained effort including over 50+ years of research has resulted in the approval of a PARP 
inhibitor for the treatment of BRCA mutated ovarian cancer (green). This success was preceded by 
the downfall of iniparib, the most promising candidate for PARP inhibition in the clinic at the time 
which later turned out not to be a bona fide PARP inhibitor (red). 3-AB = 3-AminoBenzamide (PARP 
inhibitor), PTEN = Phosphatase and TENsin homolog (protein), TNBC = Triple Negative Breast 
Cancer, BRCA = BReast CAncer genes 1 and 2, DMS = DiMethyl Sulfide, HR = Homologous 
Recombination, PARPi = PARP inhibitor, FDA = Federal Drug Administration (USA). 






Figure 1-5 The Mitotic Spindle during Metaphase 
During metaphase, the mitotic spindle is responsible for aligning the chromosomes up along the 
metaphase plate, as shown. PARPs are involved in this process at the level of telomere and 
centromere resolution (during anaphase), as well as organization of the centrosome. PARPs are 








Figure 1-6 Parthanatos: PAR-induced cell death 
Poly(ADP-ribose) has been implicated in cell death, termed Parthanatos: free PAR is released into 
the cytoplasm, triggering the release of apoptosis inducing factor (AIF), which then moves to the 






Figure 1-7 PARP inhibitors show therapeutic promise beyond cancer. 
Findings from the last 25 years which have built a case for the exploration of PARP inhibitors for the 
treatment of neurotrauma (blue), neurodegeneration (purple), autoimmune disorders (red) and 
myocardial infarction (green). CSF = Cerebral Spinal Fluid, ALS = Amyotrophic Lateral Sclerosis, 
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Poly(ADP-ribose), or PAR, is a cellular polymer implicated in DNA/RNA metabolism, cell death, 
and cellular stress response via its role as a post-translational modification, signaling molecule, and 
scaffolding element. PAR is synthesized by a family of proteins known as Poly(ADP-ribose) 
Polymerases, or PARPs, which attach PAR polymers to various amino acids of substrate proteins. 
The nature of these polymers (large, charged, heterogeneous, base-labile) has made these attachment 
sites difficult to study by mass spectrometry. Here we propose a new pipeline which allows for the 
identification of mono(ADP-ribosyl)ation and poly(ADP-ribosyl)ation sites via the enzymatic 
product of phosphodiesterase-treated ADP-ribose, or phospho(ribose). The power of this method 
lies in the enrichment potential of phospho(ribose) – which we show to be enriched by 
phosphoproteomic techniques when a neutral buffer, which allows for retention of the base-labile 
attachment site, is used for elution. Through the identification of PARP-1 in vitro automodification 
sites as well as endogenous ADP-ribosylation sites from whole cells we have shown ADP-ribose can 
exist on adjacent amino acid residues as well as both lysine and arginine in addition to known acidic 
modification sites. The universality of this technique has allowed us to show that enrichment of 
ADP-ribosylated proteins by macrodomain leads to a bias against ADP-ribose modifications 
conjugated to glutamic acids, suggesting that the macrodomain is either removing or selecting against 
these distinct protein attachments. Ultimately, the enrichment pipeline presented here offers a 
universal approach for characterizing the mono and poly(ADP-ribosyl)ated proteome. 
2.2 Introduction 
ADP-ribose (ADPr) is a post-translational modification which is synthesized by a family of 
ADP-ribosyltransferases[1], commonly known as Poly(ADP-ribose) Polymerases, or PARPs. These 
modifications are derived from the hydrolysis of NAD+ and exist in both the monomeric and 
polymeric form, the latter of which is made up of 2-200 ADP-ribose subunits. The canonical role for 
this polymer has been in the identification and repair of DNA nicks and double-stranded breaks via 
activation of the founding member of the PARP family, PARP-1[2]. Indeed, this role has ushered in 
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PARP-1 as a chemotherapeutic target, as the loss of PARP-1 sensitizes cells to genomic assault by 
established chemotherapeutic and radiation-based treatment[3]. It is worth noting, however, that 
PAR’s cellular role has expanded beyond DNA repair into regulation of (among others) apoptosis[4], 
chromatin structure[5], synthesis of DNA/RNA[6, 7], telomere maintenance[8], protein 
degradation[9], and microRNA activities[10]. Not surprisingly, the increase in understanding of 
PAR’s biological roles has led to recognition of its therapeutic potential beyond modulation of DNA 
damage, including the treatment of necrosis and inflammation[11]. PAR’s relative, mono(ADP-
ribose), is far less studied but has received increasing attention due to a number of recent studies 
which have identified the enzymes which reverse mono(ADP-ribosylation) as well as novel roles for 
mono(ADP-ribose) in the cell[12]. In an effort to aid in the understanding of the mono and 
poly(ADP-ribosyl)ated proteome we have looked to mass spectrometry to define the molecular basis 
of ADP-ribosylation, and will begin by characterizing the poly(ADP-ribosylation) (or PARylation) 
activity of human PARP-1 (hPARP-1). 
The hurdles which have kept mass spectrometry and proteomics from becoming universal 
tools for studying PARylation have to do with the physical properties of the modification itself: 
firstly, the modification can expand linearly or by branching and vary dramatically in length, resulting 
in a large, heterogeneous polymer without a defined mass. Secondly, many of the amino acid 
attachment sites are base-labile[13], preventing researchers from exposing the modified proteins or 
peptides to basic solutions which are commonly used in proteomic sample preparations. Finally, the 
modification is dynamic, with basal levels existing below the level of detection of most molecular 
tools used in proteomics. One recently published approach to identify ADP-ribosylation sites by 
mass spectrometry paired boronate enrichment of ADP-ribosylated proteins with subsequent release 
of mono and poly(ADP-ribose) from substrates by hydroxylamine[14]. This elution strategy breaks 
ester bonds between the ADP-ribose subunits and the carboxyl groups of aspartate and glutamate 
residues, leaving a characteristic 15.01 Da mass signature on the modified residue. Notably, this 
approach cannot identify non-acidic ADP-ribosylated residues and up to 33% of total ADP-
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ribosylated amino acid residues have been shown to be hydroxylamine-insensitive[15]. In particular 
lysine residues are important for the in vitro and in vivo activation of PARP-1[16, 17], as well as 
substrate regulation by PARPs, for example chromatin remodeling via PARylation of the lysine 
residues on histone tails[18]. 
Because a global approach to identify all possible ADP-ribosylation sites is still needed we 
have developed an enrichment protocol based on the digestion of ADP-ribose by snake venom 
phosphodiesterase (SVP), a pyrophosphatase which cleaves ADPr subunits down to phospho(ribose) 
and 5’-AMP[19]. This digestion produces a single phospho(ribose) group at the site of modification 
which can be identified by mass spectrometry as an adduct of 212.01 daltons[20]. Given the similarity 
of phospho(ribosyl) and phosphate groups, we reasoned that existing phosphoproteomic techniques 
may be used to enrich phospho(ribosyl)ated peptides. Indeed a 2010 phosphoenrichment study 
which utilized immobilized metal affinity chromatography (IMAC) to enrich phosphopeptides was 
searched in 2012 for a co-enrichment of ADP-ribose and/or phosphoribose, both of which were 
found to have been enriched[21, 22]. More recently, Chapman et al. demonstrated the feasibility of 
this approach to identify PARylation sites on a purified, automodified human PARP-1[23]. Here we 
have independently tested and validated this approach to identify ADP-ribosylation sites; we further 
compared three commercially available phosphoenrichment matrices and their use in enriching and 
characterizing phospho(ribosyl)ated peptides of hPARP-1 from a complex background of HeLa 
whole cell lysate. Finally we have demonstrated the application of this method to identify 
endogenous mono and poly(ADP-ribosyl)ation sites by mass spectrometry, yielding both known and 
novel acceptors of ADP-ribose, including a number which identify ADP-ribose on arginine residues. 
2.3 Materials and Methods 
Expression and purification of HisPARP-1  
Method was adapted from Langelier et al. [24], briefly: 6 liters of His-PARP-1 expressing DE3 cells 
were lysed in a cell homogenizer in the presence of 0.1% NP-40, 20 U/mL DNAse I, 5 mM MgCl2, 1 
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μM bestatin, 1 μM pepstatin A, and 1x Roche cOmplete EDTA-free protease inhibitor. Lysate was 
cleared by centrifugation and loaded onto an ÄKTA FPLC (GE, 18-1900-26) with a pre-equilibrated 
5 mL HisTrap FF Crude column (GE, 17-5286-01) where it was washed with 10 column volumes of 
loading buffer (20 mM NaPO4 pH 7.4, 1M NaCl, 0.5 mM TCEP, 40 mM imidazole pH 7.4, 1% 
glycerol, 1x Roche cOmplete EDTA-free protease inhibitor) before being eluted in 2 column 
volumes of elution buffer (20 mM NaPO4 pH 7.4, 0.5 M NaCl, 0.5 mM TCEP, 0.5 M imidazole pH 
7.4, 1% glycerol). Eluted samples were diluted 1:1 in heparin no-salt buffer (50 mM Tris pH 7.0, 0.1 
mM Tris-(2-Carboxyethyl)phosphine, 1% glycerol) and loaded onto a pre-equilibrated 5 mL heparin 
column (GE, 17-0407-01), washed with 5 volumes of low-salt buffer (50 mM Tris pH 7, 0.1 mM 
TCEP, 250 mM NaCl) and eluted over a gradient from 0-70% high-salt buffer (50 mM Tris pH 7, 0.1 
mM TCEP, 1M NaCl, 1% glycerol). Desired fractions were pooled and concentrated using a spin 
concentrator (30,000 MWCO, Amicon Z648035) before being loaded onto a pre-equilibrated size 
exclusion column (GE, Superdex 200/10/300 GL) in size purification buffer (25 mM HEPES pH 8, 
0.1 mM TCEP, 150 mM NaCl), desired fractions were pooled and stored at -80˚C. All FPLC results 
were analyzed with UNICORN 5.01 (Build 318). 
Purification of Snake Venom Phosphodiesterase I (SVP) 
Protocol was adapted from Oka et al[25], briefly: (2) 100 unit vials of Crotalus adamanteus 
Phosphodiesterase I (Worthington, LS003926) were dissolved into 1 mL of loading buffer (10 mM 
Tris-Cl pH 7.5, 50 mM NaCl, 10% glycerol) and then loaded onto a pre-equilibrated 1 mL HiTrap 
blue sepharose column (GE, 17-0412-01), washed with 5 column volumes of loading buffer and then 
5 column volumes of elution buffer (10 mM Tris-Cl pH 7.5, 50 mM NaCl, 10% glycerol, 150 mM 
potassium phosphate). Desired fractions were pooled, dialyzed against loading buffer, and stored at -
80˚C. If enzyme preps were to be used to treat denatured proteins an additional purification was 
needed to remove any contaminating proteases: samples were dialyzed into size exclusion 
chromatography buffer (10 mM Tris-Cl pH 7.3, 50 mM NaCl, 15 mM MgCl2, 1% glycerol) and 
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resolved over a SuperDex 200/10/300 GL (GE Healthcare) using an ÄKTA FPLC (GE, 18-1900-
26), desired fractions were pooled and stored at -80˚C. All FPLC results were analyzed with 
UNICORN 5.01 (Build 318). 
Preparing oligos for in vitro PARP-1 activation  
Oligo sequences were from Langelier et al [24]. Forward (GGGTGGCGGCCGCTTGGG) and 
reverse (CCCAAGCGGCCGCAACCC) oligos were mixed 1:1 in H2O, heated to 95˚C for 2 minutes 
and then ramp cooled to 25˚C over 45 minutes. 
Automodification of HisPARP-1 in vitro 
HisPARP-1 was attached to Promega MagneHis beads (1 μg PARP-1/μL beads/5 μL attachment 
buffer) for 2 hours at 4˚C in attachment buffer (50 mM Tris pH 7.4, 1% Tween, 0.2mM DTT, 10% 
glycerol, 10 mM MgCl2). Beads were washed twice with 100 μL wash buffer (50 mM sodium 
phosphate buffer pH 7.4, 200 mM NaCl, 5 mM imidazole pH 7.4) and then exposed to 30 μM (0.6% 
hot) 32P β-NAD+ in automodification buffer (20 mM Tris pH 7.5, 50 mM NaCl, 50 μM TCEP, 5 
mM MgCl2, 1.2 μM annealed DNA) for 10 minutes followed by a chase of 2 mM cold β-NAD+ for 
60 minutes, all at 25˚C rotating at 500rpm. For SDS-PAGE beads were washed twice in 100 μL wash 
buffer and eluted into 15 μL of 1x SDS-PAGE buffer, separated on an in-house 6-10% SDS-PAGE 
gel, fixed overnight (50% methanol, 10% acetic acid), washed for 30 minutes (H2O), stained with 
Pro-Q Diamond Phosphoprotein stain (Invitrogen, MP 33300) for 1 hour, destained for 3x30 
minutes (20% acetonitrile, 50 mM sodium acetate pH 4), washed for 10 minutes (H2O) and imaged 
on a Fuji FLA7000 (filter: O580, wavelength: 532nm). Pro-Q Diamond staining was validated based 
on comparison to Pro-Q Diamond PeppermintStick ladder (Life Technologies, P27167). Total 
protein was determined by Coomassie Blue staining (Invitrogen LC6060) and 32P-labeling was 
determined by overnight exposure against a phosphor-screen (GE, BAS-III 2040) followed by 
imaging on a Fuji FLA7000 (IP). Western blotting for poly(ADP-ribose) was performed by 
transferring proteins (Invitrogen XCell II Blot Module) from an in-house 6-10% SDS PAGE gel to a 
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nitrocellulose membrane (Bio-Rad), membranes were blocked in 5% milk in PBS before being 
incubated in primary antibody (anti-PAR, clone LP-9610 from BD Biosciences) for 1 hour at room 
temperature, rinsed in PBS-T, and then incubated in secondary antibody (Anti-Rabbit 800 nm from 
LI-COR Biosciences) for 1 hour before being imaged on an Odyssey CLx and analyzed in Image 
Studio (from LI-COR, version 2.0). 
SVP digestion of in vitro PARylated HisPARP-1 
1 μg of PARylated HisPARP-1 was treated with 500 mUnits of purified SVP in SVP digestion buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 15 mM MgCl2, 20 mM 3-aminobenzamide) for 2 hours at 25˚C, 
500rpm. 
Testing loss of PARylation by exposure to phosphoelution conditions  
hPARP-1 was induced to automodify in vitro (as described above), mixed in a 1:2 ratio with BSA and 
1 μg hPARP-1/2 μg BSA were aliquoted and exposed to either 5% ammonium hydroxide, 500 mM 
KH2PO4 pH 7, or automodification buffer (control) in a total volume of 10 μL for 5 minutes. 
Reactions were quenched by adding 1 mL of ice-cold precipitation buffer (0.02% deoxycholate, 4% 
Triton X-100, 10% TCA) and stored at -20˚C for 2 hours before being pelleted by centrifugation at 
4˚C and decanted. Pellets were washed with ice cold acetone containing 20 μg/mL glycogen as a 
carrier, stored at -20˚C for 30 minutes, pelleted, decanted, dried by speedvac and resuspended in SDS 
Running Buffer. For SDS-PAGE analysis an equal volume of 2x SDS-PAGE buffer was added to 
samples for analysis on an in-house 6-10% Tris-Glycine gel. 
Cell culture 
HeLa cells (Kyoto) were grown in arginine and lysine free DMEM (Pierce) containing 10% dialyzed 
FBS (Sigma), 0.4 mM arginine (13C615N4 from Cambridge, 12C614N4 from Sigma) and 0.8 mM lysine 
(13C615N2 from Isotec, 12C614N2 from Sigma).  Trophoblast stem cells from PARG knockout mice 
(E3.5 from 129.SVJ mice, acquired from Dr. David Koh of Johns Hopkins University[26]) were 
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grown in arginine and lysine free RPMI 1640 (Pierce) containing 16% dialyzed FBS (Sigma), 0.4 mM 
arginine (123C615N4 from Cambridge, 12C614N4 from Sigma), 0.8 mM lysine (13C615N2 from Isotec, 
12C614N2 from Sigma), 1 mM sodium pyruvate (Life Technologies), 2 mM L-glutamine (Life 
Technologies), 25 units/mL penicillin (cellgro), 25 units/mL streptomycin (cellgro), 100 uM 
monothioglycerol (Sigma), 1 μg/mL heparin sulfate, 25 ng/mL FGF-4 and 0.5 mM benzamide 
(Sigma).  PARG knockout cells were grown without benzamide for 48 hours before harvesting.  All 
cells were treated with 5 mM N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, from AccuStandard) 
for 5 minutes before being washed three times with ice cold PBS (Gibco) and lysed in either 6M 
guanidine-hydrochloride (Sigma), 8M urea (Sigma) or lysis buffer (50 mM Tris pH 7.5, 0.4 M NaCl, 1 
mM EDTA, 1x EDTA-free cOmplete protease-inhibitor from Roche, 1% NP-40, 1 μg/mL ADP-
HPD and 0.1% sodium deoxycholate).  Cells lysed in either guanidine-hydrochloride or urea were 
subjected to sonication in an ice bath for 10 minutes with 30 second breaks between 30 second 
cycles (Bioruptor Standard). Cells lysed in lysis buffer were left on ice for 10 minutes.  Following lysis 
all cell debris was cleared by centrifugation. 
PAR enrichment by macrodomain 
2 mg of whole cell lysate in 1x lysis buffer (50 mM Tris pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1x 
EDTA-free cOmplete protease-inhibitor from Roche, 1% NP-40, 1 μg/mL ADP-HPD and 0.1% 
sodium deoxycholate) were incubated at 5 mg/mL with 40 μL of macrodomain-conjugated agarose 
beads (Tulip #2302) at 4˚C overnight before being washed three times with wash buffer (50 mM Tris 
pH 7.5, 0.4 M NaCl and 0.1% sodium deoxycholate) and eluted by 8M urea pH 7. 
SVP digestion of endogenous proteins with or without protein standard (hPARP-1) 
All proteins were denatured in 8M urea pH 7 for 10 minutes at 37˚C before being reduced in 1 mM 
Tris-(2-Carboxyethyl)phosphine (Life Technologies) for 10 minutes and then alkylated in 2 mM 2-
chloroacetamide (Sigma) for 10 minutes in the dark.  If automodified hPARP-1 is to be added as a 
standard it is prepared the same way and added into the lysate background at this point. Samples 
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were then diluted to a final concentration of 1M urea, 50 mM NaCl, 15 mM MgCl2, 1 mM CaCl2, and 
0.2 M Tris pH 7.3. 5 μg of purified SVP were added for each mg of whole cell lysate and incubated 
for 2 hours at 37˚C.  
In-solution protein digestion 
Samples in 1 M urea, 0.2 M Tris-Cl pH 7.3, 1 mM CaCl2, 15 mM MgCl2, and 50 mM NaCl are  
treated with endoproteinase LysC (Wako) 1:50 enzyme:substrate. After 1 hour trypsin (Sigma) was 
added at a 1:50 enzyme:substrate ratio, the entire reaction was incubated overnight. Reaction was 
stopped by adding an equal volume of desalting solvent A (5% acetonitrile, 0.1% TFA) and desalted 
on a C18 StageTip and eluted in desalting solvent B (80% acetonitrile, 0.1% TF) as in Rappsilber et al 
[27]. 
Phosphoenriching peptide standards from HeLa WCL peptide background  
HeLa cells were scraped into 6M Gnd-HCl, lysed by sonication and cleared by centrifugation. 300 μg 
of protein was then reduced, alkylated and in-solution digested by LysC and Trypsin as described in 
“In-solution protein digestion”. To this mixture of peptides 30 μg of peptides from automodified, 
SVP-treated hPARP-1 and 10 μg of peptides from bovine casein were added. This mixture was then 
sampled as input and split into 3 equal volumes which were enriched by either IMAC (Sigma PHOS-
Select beads) or MOAC (GL Sciences or GlySci tips containing ZirChrom TiO2 beads). IMAC 
samples were enriched as in Villen et al 2008[28], briefly: they were incubated for 1 hour, shaking at 
25˚C, on 50 μL of PHOS-Select beads in binding buffer (0.1% formic acid, 40% acetonitrile). These 
beads were then transferred to a pre-equilibrated StageTip[27] where they were washed with binding 
solvent three times, acidified with 1% FA and eluted onto the StageTip with 0.5M potassium 
phosphate pH 7, where they were acidified with 1% FA again and washed with desalting solvent A 
(5% acetonitrile, 0.1% TFA). They were then eluted with Desalting Solvent B (80% acetonitrile, 0.1% 
TFA). MOAC samples were enriched either by GL Sciences or GlySci TiO2 tips, both by their 
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manufacturer’s protocols with the adaptation that they were eluted with 0.5M potassium phosphate 
pH 7. 
NanoLC-MS/MS analysis  
Peptides were separated on a Thermo-Dionex RSLCNano UPLC instrument with ~10 cm x 75 
micron ID fused silica capillary columns with ~10 micron tip opening made in-house with a laser 
puller (Sutter) and packed with 3 micron reversed phase C18 beads (Reprosil-C18.aq, 120 Angstroms, 
Dr. Maisch) with a 90 min gradient of 3-35% B at 200 nL/min. Liquid chromatography (LC) solvent 
A was 0.1% acetic acid and LC solvent B was 0.1% acetic acid, 99.9% acetonitrile. MS data was 
collected with a Thermo Orbitrap Elite. Data-dependent analysis was applied using Top5 selection 
and fragmentation was induced by CID and HCD. Profile mode data was collected in all scans. 
Database search of MS/MS spectra for peptide & protein identification  
Raw files were analyzed by MaxQuant version 1.4.0.8 using protein, peptide and site FDRs of 0.01 
and a score minimum of 40 for modified peptides, 0 for unmodified peptides; delta score minimum 
of 17 for modified peptides, 0 for unmodified peptides. Sequences were searched against the UniProt 
Human Database (definitions updated May 29th, 2013). Endogenous phospho- and phosphoribose 
peptide lists were further restricted by a delta ppm of +/- 2σ from each respective data set (average 
and standard deviation were calculated from the complete tandem mass spectra (MS/MS) list of 
identified peptide precursors) and the expected heavy/light ratios (greater than or less than 1 for 
heavy or light data sets, respectively). MaxQuant search parameters: Variable modifications included 
Oxidation (M), Acetylation (Protein N-term), phosphorylation (STY) and phosphoribosylation 
(DEKR).  Phosphoribosylation (DEKR) allowed for neutral losses of H3PO4 (phosphoric acid, 97.98 
daltons) and C5H9PO7 (phosphoribose, 212.01 daltons).  Carbamidomethyl (C) was a fixed 
modification. Max labeled amino acids was 3, max missed cleavages was 2, enzyme was Trypsin/P, 




SVP Treatment of PARylated Substrates Generates Phospho(ribosyl)ated Proteins, which 
can be Stained by a Phosphoprotein Dye, Pro-Q Diamond  
 As a model for protein PARylation we utilized hPARP-1, a Poly(ADP-ribose) Polymerase 
capable of auto-poly(ADP-ribosyl)ation. Exposure of hPARP-1 to 32P labeled β-NAD+ resulted in 
an increase in molecular weight of hPARP-1 above its unmodified mass of 113 kDa which was 
correlated with the 32P signal observed in the autoradiograph, indicating incorporation of 32P-ADPr 
via hPARP-1 automodification (see Figure 2-1 panels a and b, lane 1 vs. lane 2). Upon treatment with 
SVP (lane 3), the majority of the “smear” was lost by both Coomassie blue and 32P detection with an 
accompanied increase in the intensity of the Coomassie-stained band at the expected size of 
unmodified hPARP-1. This result demonstrates SVP’s ability to break down the polymer at 
pyrophosphate bonds, potentially reducing the polymer entirely to the phospho-ribosyl group on the 
modified amino acid residue of PARylated proteins. 
 Because of the similarity of phospho(ribose) and phosphate groups, we posited that the 
phospho(ribosyl)ated hPARP-1 might share properties with phosphoproteins. To test this 
hypothesis, we used the phosphoprotein gel stain, Pro-Q Diamond, to stain the polyacrylamide gel in 
Figure 2-1a (Figure 2-1c). While unmodified hPARP-1 and modified hPARP-1 were weakly stained 
with Pro-Q Diamond, the signal was significantly increased for SVP-treated hPARP-1 (Figure 2-1c, 
lanes 1-3). The phospho-specificity of the dye was confirmed with the two phosphoprotein controls, 
-casein, in the protein molecular weight ladder (Figure 2-1c, marker). To confirm 
that the staining associated with SVP-treated hPARP-1 is due to the presence of phosphate groups, 
we treated the samples with calf intestinal phosphatase (CIP). As expected, upon removal of the 
phosphate groups by CIP, the resultant ribosylated hPARP-1 was no longer stained by Pro-Q 
diamond (Figures 2-1d and 2-1e). These data suggest that SVP treatment of PARylated substrates 
produces phospho(ribose) groups, and that the resultant phosphate groups may have similar 
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physicochemical properties to phosphate groups in phosphoproteins. We then sought to examine 
our ability to enrich these phospho(ribose) groups using phosphopeptide enrichment strategies 
Neutral phosphate buffer preserves base-labile ADP-ribose bonds and serves as a safe 
alternative to ammonia for peptide elution  
 Popular phosphoproteomic approaches use immobilized metal affinity chromatography 
(IMAC) or metal oxide affinity chromatography (MOAC) to enrich phosphopeptides, followed by 
elution with ammonium hydroxide. Unfortunately, ammonium hydroxide is highly basic and 
therefore releases ADPr from glutamic and aspartic acid residues[13]. For this reason we considered 
an alternative elution condition, neutral phosphate buffer, which has been used previously to 
competitively elute phosphopeptides[28].  To assess ADPr stability in the presence of phosphate 
buffer 32P-labeled, automodified hPARP-1 was exposed to either 5% NH4OH, 0.5M KH2PO4 pH 7 
or control (automodification buffer containing 20 mM Tris pH 7.5). As can be seen in Figure 2-2 
both the control and the neutral phosphate buffers maintained hPARP-1 in its PARylated form 
(smeared) while ammonia hydrolyzed PAR, returning much of the hPARP-1 to its native size by 
Coomassie (Figure 2-2 panel a) and removing 32P-labeled PAR as shown in the autoradiograph 
(Figure 2-2 panel b). These results suggest that the standard alkaline conditions in phosphoproteomic 
elution protocols result in the loss of PARylation while the neutral phosphate buffer preserves the 
ADPr-protein bond and should be a safe method to elute phospho(ribosyl)ated peptides from 
phospho-affinity matrices. 
Quantitative comparison of phosphoproteomic techniques in co-enriching 
phospho(ribosyl)ated peptides and phosphopeptides 
 Next, we explored whether phospho(ribosyl)ated peptides can be enriched from cellular 
complex mixtures using phosphoenrichment matrices. SVP-treated hPARP-1 was mixed with HeLa 
cell lysate which was SILAC[29] labeled in “heavy” culture medium containing 13C6,15N2-Lysine and 
47 
  
13C6,15N4-Arginine (Supplementary Figure 2-1). Because we expect the human hPARP-1 spectra to be 
derived from SVP-treated, unlabeled “light” hPARP-1 samples, we can verify the source of the 
peptide by SILAC state. As a positive phosphoenrichment control, peptides from known 
phosphoprotein standards, bovine caseins, were also added to the whole cell lysate background. The 
complex peptide mixture was subjected to three commercially available phosphoenrichment matrices 
– (1) Sigma PHOS-Select Iron Affinity Gel (PS), (2) GL Science Titansphere Phos-TiO2 Tips (GL) 
and (3) GlySci Phosphopeptide NuTip using Zirchrom Titanium Dioxide beads (ZC). In each case, 
peptides were eluted with 0.5M potassium phosphate buffer at pH 7.0 to preserve the labile bond 
between phospho(ribose) and acidic amino acids. Mass spectrometry data was collected on an 
Orbitrap and fragmentation was induced by both Collision-Induced Dissociation (CID) and Higher-
energy C-trap Dissociation (HCD).  
 Overall, our complex background consisted of 44,655 peptides from 2,148 proteins and 
included 3,421 endogenous phosphopeptides (see Supplementary Tables 2-2, 2-3, 2-4).  Out of this 
background we identified 47 unique phosphopeptides from the spiked-in phosphoprotein standards 
(bovine caseins) using all enrichment techniques (Supplementary Table 2-1, Figure 2-3a and 
Supplementary Figures 2-2a,e). While PHOS-Select contributed the most unique peptide 
identifications (36%) both GL Sciences and Zirchrom found peptides which would not have 
otherwise been identified (2% and 13%, respectively). This stands in contrast to the 29 unique 
hPARP-1 phospho(ribosyl)ated peptides, of which nearly 60% were found exclusively through 
enrichment by PHOS-Select (Supplementary Table 2-1, Figure 2-3b and Supplementary Figures 2-2b, 
f) and only a single peptide (3%) was found solely by an alternative enrichment (Zirchrom). Further 
assessment of the PHOS-Select enrichment profile reveals that the 39 unique phosphopeptides and 
28 unique phospho(ribose) peptides found in the PHOS-Select eluate entirely overlapped with the 
small number of peptides which were found in the respective input and flowthrough analyses 
(Figures 2-3c,d and Supplementary Figures 2-2c,d,g,h).  
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 In order to determine whether the protocol proposed here is as robust for 
phospho(ribosyl)ated peptides as phosphopeptides a serial enrichment was performed which 
included re-enriching the flowthrough sample multiple times to quantify the depletion of these two 
classes of target peptides (figure 2-4). Automodified hPARP-1 was again used as the PAR standard 
however this time the PARylated hPARP-1 was denatured in 8M urea, reduced and alkylated prior to 
being added in to the whole cell lysate background (figure 2-4a).  This denaturation step served to 
completely inactivate hPARP-1 (see supplementary figure 2-3) thus allowing us to perform SVP 
digestion of the whole cell lysate and the PARylated standard in the same mixture. Furthermore the 
His-tag on hPARP-1 allowed us to isolate a portion of the standard back out of the mixture both 
before and after SVP digestion, these samples served as a quality control step as the loss of PAR and 
the formation of phospho(ribose) could be monitored by SDS-PAGE and western blot (see figures 
2-4 panels b-d). As shown in figure 2-4e both classes of peptides are depleted from the background 
population at similar rates (as opposed to phosphopeptides being enriched preferentially prior to 
phospho(ribosyl)ated peptides), indicating that the IMAC method proposed is truly a dual 
enrichment of both phospho- and phospho(ribosyl)ated peptides. It should be noted that the 
peptides identified in this study include both those from the hPARP-1 standard as well as the 
endogenous phospho- and phospho(ribosyl)ation sites from the MNNG-treated murine PARG 
knockout cells used to generate the heavy-labeled complex background. For a complete list of 
endogenous phospho- and phospho(ribosyl)ated peptides see supplementary tables 2-5 and 2-6. 
Characteristics of Phospho(ribosyl)ated peptides 
 Among the phospho(ribosyl)ated peptides identified from the hPARP-1 standard, 20 unique 
sites were modified. Many of these sites were outside of the automodification/BRCT domains that 
are known to be heavily PARylated[30] (Table 2-1), and in fact, over one-third of the sites identified 
(7/20) are in the second zinc finger which is not strictly required for PARP-1 activation [31]. Of the 
20 potential PARylation sites 1 arginine, 3 lysine, 4 aspartate and 12 glutamate residues were 
identified. While the basic sites may seem surprising we emphasize that the inherent NADase activity 
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of PARP-1 [32] has the potential to create free ADP-ribose, a molecule which can spontaneously 
modify basic sites independent of PARP-1’s conjugation activity [33]. As this non-enzymatic 
mechanism of ADP-ribosylation is still under investigation we believe the ability of this method to 
identify the presence of ADP-ribose on both basic and acidic modifications will prove highly useful 
in elucidating methods of ADP-ribose modification and automodification. 
 Among the 20 hPARP-1 automodification sites identified 10  were independently verified as 
endogenous sites in DNA damaged cells in a recent analysis [14]. While most peptides presented with 
a single phospho(ribose) there were 3 examples of doubly phospho(ribosyl)ated peptides which 
demonstrated the ability of hPARP-1 to place these large, negatively charged polymers within close 
proximity of each other (Supplementary Spectra). A notable example of this is the dual modification 
of E488 and E491, PARP-1 automodification sites which have been independently verified by a 
number of groups, including Zhang et al who identified them as endogenous ADP-ribosylation sites 
(Table 2-1). Here, we have shown the fragmentation patterns of the unmodified, singly modified and 
doubly modified forms of this peptide by both CID (Figure 2-5) and HCD (Supplementary Figure 2-
4) indicating the shift in molecular weight corresponding to a single (circle) or a double (square) 
phospho(ribose) group. The doubly-modified peptide also demonstrates the potential for neutral loss 
of phosphoric acid (H3PO4 97.98 daltons) and phospho(ribose) (C5H9PO7, 212.01 daltons) from the 
parent ion upon fragmentation (Figure 2-5, Supplementary Figure 2-5) - these neutral losses were 
observed in 73% (16/22) of the spectra annotated for validation of the PARP-1 automodification 
sites (Supplementary Spectra), most often showing up in the presence of the modified form, 
indicating that neutral loss was not complete. Considering how common these neutral losses are the 
authors advise including them in mass spectrometry search criteria. 
 Our analysis identified three lysine modifications: two novel, one previously reported in a 
2009 mutagenesis screen[16] (Table 2-1). Two of these were found at the C-terminus of the peptide, 
suggesting that the phospho(ribosyl)ated residue did not prevent proteolytic cleavage at the modified 
lysine, in our case by a combination of LysC and Trypsin. To confidently assign the novel 
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PARylation site K486, its CID fragmentation pattern was compared to an unmodified version of the 
same peptide – revealing a b-ion series which was unmodified in both spectra and a y-ion series 
which contained the 212.01 Da shift indicative of a phospho(ribose) addition to every y-ion fragment 
(figure 2-6). The extensive b- and y-ion series provide strong evidence of the phospho(ribose) 
modification on the peptide C-terminal lysine, demonstrating (1) the availability of 
phospho(ribosyl)ated lysines for protease cleavage and (2) the ability of PHOS-Select to enrich 
phospho(ribosyl)ated lysines.  
ADP-ribosylation sites identified from whole cells 
 In order to establish a pipeline for identifying endogenous sites of mono and poly(ADP-
ribosyl)ation HeLa cells were SILAC labeled and then treated with the DNA damaging agent 
MNNG to induce PARylation before being subjected to an affinity pull-down by the mono and 
poly(ADP-ribose) binding macrodomain from Af1521[34].  ADP-ribosylated proteins were then 
denatured before being treated with SVP and then digested with a mixture of the proteases LysC and 
trypsin.  These peptide mixtures were then split in half and either enriched over a charged or a 
stripped IMAC resin with the elution from the stripped resin serving as a nonspecific background 
control for the eluted peptides which had come off of the charged IMAC resin (see figure 2-7a). 
Since both forward and reverse labeling patterns were used the strongest hits from the database 
showed up in both populations, as demonstrated in figures 2-7b and 2-7c.  A representative spectrum 
for phosphoribosylated R4 from Serine/Arginine rich Splicing Factor 2 (SRSF2) is shown with its 
parent ion in figures 2-7b and 2-7d. Notably, the pipeline described in 2-7a was performed in parallel 
on an MNNG-treated trophoblast stem cell line from a PARG knockout mouse model [26], 
producing 22 unique endogenous phospho(ribosyl)ated peptides, two of which (containing R4 from 
SRSF2 and R199 from heterogeneous nuclear ribonucleoprotein U, HNRNPU) overlapped with 
those found from the HeLa preparation (see supplementary table 2-5). All of the 
phospho(ribosyl)ated peptides identified from these samples were found in the IMAC enriched 
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fractions, indicating that macrodomain enrichment followed by SVP digestion was not sufficient for 
site identification.  
 In order to determine whether the macrodomain enrichment was necessary for site 
identification the same analysis was done with the ADPr affinity purification omitted, again utilizing 
both the human wildtype and murine PARG knockout cell lines described above. 22 unique 
phospho(ribosyl)ated peptides were identified from these preparations, including the same 
HNRNPU peptide containing R199 found following macrodomain enrichment (it was again found in 
both cell lines), showing that the macrodomain enrichment is not only insufficient on its own for site 
identification but also that it is not necessary. Furthermore, a comparison of the macrodomain 
enriched versus unenriched data sets revealed a bias in the amino acids which served as attachment 
sites for phospho(ribose); the macrodomain enrichment appears to have shifted the profile of ADP-
ribosylated amino acids away from glutamic acid residues (figure 2-8, source data can be found in the 
supplementary text and supplementary table 2-5). This shift indicates that the macrodomain is either 
selecting against ADP-ribosylated glutamic acid in favor of other amino acid attachment sites or that 
it is actually removing the ADP-ribose attachment from glutamic acids. The latter hypothesis lines up 
with recently published work showing that the macrodomain of Af1521 possesses ADP-
ribosylhydrolase activity, and suggests that this activity may be targeted toward glutamic acid sites of 
ADP-ribosylation [35, 36].  
2.5 Discussion 
 The expanding relevance of PARylation in cellular processes has led researchers to look 
beyond the canonical role of DNA repair when considering the consequences of altered PARylation 
levels [37]. To this end, the most powerful tool for studying global changes in post-translational 
modifications continues to be systematic analyses of proteomes by mass spectrometry. Unfortunately 
the widespread use of proteomics and mass spectrometry has not yet been established in the field of 
PARylation due to challenges relating both to the modification itself – which may be labile, large, and 
highly charged – and to the low levels of PARylation which exist below the threshold of most 
52 
  
analytical techniques. In response, enrichment techniques have been developed which have allowed 
researchers to study the PARylated proteome with the caveat that the identified proteins are either 
PAR acceptors or PAR binders; due to the lack of site identification in these studies verification of 
which class these proteins belong to is both tedious and, in some cases, impossible [38, 39]. Recently 
a study has demonstrated the feasibility of identifying mono and poly(ADP-ribosyl)ation sites in a 
large proteomic screen which combines enrichment of ADP-ribosylated substrates by boronate 
chromatography with the removal of ADPr from substrates by hydroxylamine; this chemical 
treatment allows for subsequent identification of acidic ADP-ribosylation sites by the diagnostic 
15.01 Da hydroxamic acid derivative left behind [14]. The limitation in this study was that ADP-
ribosylated lysine and arginine could not be detected as only acidic residues were left with the 
hydroxamic acid tag. In contrast, our pipeline can identify ADP-ribosylation attachment sites on both 
acidic and basic residues; it should also be noted that this universality allows for the discovery of 
novel amino acid attachment sites for ADPr beyond these acids and bases, the existence of which has 
not been ruled out. We believe our proposed method of enriching and identifying ADP-ribosylation 
sites addresses the need for a pipeline which is both global and definitive in identifying ADPr 
acceptors at the protein and amino acid levels.  
 The phosphoenrichment methods applied in this study have gained popularity in the 
phosphoproteomic field due to their high specificity and compatibility with both MALDI and ESI 
LC/MS. MOAC, or Metal Oxide Affinity Chromatography, has proven to enrich phosphopeptides 
more specifically than its predecessor, IMAC (Immobilized Metal Affinity Chromatography) likely 
due to the tighter binding of phosphate to the TiO2 microspheres (titanspheres) as compared to the 
chelated iron used by PHOS-Select IMAC resin [40]. This tight binding, however, may explain the 
lack of phospho- and phospho(ribose) peptides found in the eluates from the TiO2 resins used here 
(GL Sciences and ZirChrom) which have an optimal elution pH between 9.2 and 9.4 [41]. IMAC 
elution, on the other hand, is much more sensitive to competitive phosphate levels than it is to pH, 
and does not have an optimal elution pH [42]. We have demonstrated the stability of ADPr protein 
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attachment sites in neutral phosphate buffer as compared to basic NH4OH and have restricted our 
elution conditions to ensure retention of phospho(ribose) on target peptides throughout the 
enrichment. This consideration may have favored the lower-affinity phosphoenrichment matrix, 
allowing for a single enrichment protocol capable of enriching both phospho- and phospho(ribose) 
peptides, perhaps at the expense of tightly-bound phosphopeptides left on the TiO2 matrices. For 
thorough phosphopeptide analysis it may be prudent to perform a parallel enrichment with optimal 
(ie basic) elution conditions from a TiO2 matrix. 
While validating the presence of our phospho(ribosyl)ated protein sample we discovered that 
the phosphoprotein SDS-PAGE gel stain, Pro-Q Diamond, can act as an indicator of 
phospho(ribose) modified proteins. While we did not do any in-gel digests, the compatibility of Pro-
Q Diamond with downstream LC/MS analysis [43] suggests that isolation and identification of 
phopho(ribosyl)ated proteins, as well as their PAR acceptor sites, may be possible for researchers 
who wish to analyze changes in SDS-PAGE profiles. We believe this data-dependent approach 
would greatly complement the global analysis already offered by the phospho(ribose) ADP-
ribosylation tag. 
 Optimization of our phosphoenrichment protocol presented us with a database of spectra 
identifying phospho(ribosyl)ated peptides from automodified hPARP-1, ultimately yielding 20 
modified sites, eight of which are being reported for the first time. These spectra afforded us the 
opportunity to characterize phospho(ribosyl)ated peptides (and by extrapolation, ADP-ribosylation 
sites) with regard to their identification by CID- and HCD-assisted LC/MS/MS. Firstly, we 
determined that multiple PARylation sites may exist within the same peptide, suggesting hPARP-1 is 
capable of placing these large, highly charged polymers within an amino acid of each other (as in the 
hPARP-1 automodified peptide GFSLLATE*D*K, see Supplementary Spectra). The steric 
hindrance and charge-repulsion associated with neighboring PARylation sites may require a high level 
of flexibility from the protein, poly(ADP-ribose), or both. Secondly, it is worth noting that we 
identified two lysine hPARP-1 automodification sites at the C-terminal end of their respective 
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peptides, indicating that these modified lysines were available for proteolytic digestion (see 
Supplementary Table 2-2). Finally, fragmention by HCD and CID revealed the potential of 
phospho(ribose) to be partially or fully lost in the form of a phosphoric acid or phosphoribose, 
respectively (see Supplementary Figure 2-5). This loss is not complete as the fragments portraying the 
neutral loss are often accompanied by otherwise-identical fragments which have maintained the full 
modification. In the future these neutral loss fragments may serve as diagnostic indicators of peptide 
phospho(ribosyl)ation state. Recognition of these attributes will aid in the analysis of large, 
phospho(ribosyl)ated proteomes, which may present these characteristics that would allow them to 
be ignored by erroneous search parameters. 
 While demonstrating the application of this method to identify ADP-ribosylation sites from 
whole cells we validated several known sites of ADP-ribosylation recently identified by a 
complementary mass spectrometry approach [14] as well as a host of novel sites on both novel and 
known acceptors of mono and/or poly(ADP-ribose) (see supplementary table 5). One of our most 
interesting hits lies on K350 of heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), a protein 
which was first shown to be poly(ADP-ribosyl)ated in whole cells in 1982 and 12 years later was 
shown to be one of the 2 major acceptors of ADP-ribose in HeLa cells [44, 45]. More recently, 
PARylation of HNRNPA1 has been shown to affect splicing, stem cell maintenance and oocyte 
localization in drosophila, suggesting an interesting role for mammalian HNRNPA1 PARylation [46, 
47]. While there have been several proteomic studies which have identified HNRNPA1 in poly or 
mono(ADP-ribosyl)ation purification schemes [38, 39] this finding is the first indication of the site of 
PARylation on HNRNPA1 (spectrum annotated in supplementary figure 2-6). 
 In summary we have proposed and demonstrated the feasibility of a global, unbiased 
approach for characterizing the mono and poly(ADP-ribosyl)ated proteome. Our technique, based 
on the digestion of ADPr down to its phospho(ribose) attachment site, allows for enrichment at the 
peptide level of both acidic and basic ADPr acceptor sites. Furthermore we have shown that our 
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method allows researchers to find sites of ADP-ribosylation without having to knockdown ADP-
ribose hydrolases or perform an enrichment of the ADP-ribosylated proteome, steps which may 
otherwise introduce bias. Finally, this approach presents a unique opportunity to study the changes in 
the ADP-ribosylated proteome alongside the co-enriched phosphoproteome. It is our hope that the 
accessibility of the techniques employed in this enrichment pipeline will allow researchers to 
characterize global ADP-ribosylation at the level of the amino acid, ultimately resulting in a greater 
understanding of both mono and poly(ADP-ribose) function and regulation from the bottom up. 
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Figure 2-1 Visualizing phospho(ribose) tags on hPARP-1.  
(a-c) hPARP-1 automodified in vitro upon exposure to 32P-labeled NAD+, PAR formation is 
evidenced by the 32P-labeled smear above unmodified hPARP-1 (arrowheads). Upon treatment with 
SVP the smear diminishes while the native sized hPARP-1 band reappears. Staining with the 
phosphostain Pro-Q Diamond indicates that this band is carrying phospho-groups, likely 
phosphoribose. (d-e) The Pro-Q positive product of SVP-treated automodified hPARP-1 is 





Figure 2-2 Poly(ADP-ribose) is stable in the presence of neutral phosphate buffer. 
(a) Coomassie staining shows that PARylated hPARP-1 returns to its unmodified size upon 
treatment with ammonia for 5 minutes, while neutral phosphate retains the PARylation state as well 
as the control buffer (automodification buffer). (b) 32P-labeled PAR shows that the loss of PAR is 
correlated with the return of hPARP-1 to its native size. BSA (Bovine Serum Albumin) was included 
as a carrier for sample cleanup by protein precipitation, which was the method applied to 





Figure 2-3 IMAC and MOAC enrichment of phospho- & phospho(ribose) peptides. 
IMAC (PHOS-Select, PS) was compared to MOAC (both ZirChrom, ZC and GL Sciences, GL) for 
enrichment of phosphopeptides (from bovine casein) and phospho(ribose) peptides (from hPARP-1) 
out of HeLa whole cell lysate background. (a,b) Unique phosphorylated (a) and phospho(ribosyl)ated 
(b) peptides identified in eluates from the 3 methods. (c,d) Unique phosphorylated (c) and 
phospho(ribosyl)ated (d) peptides identified in the unenriched (input), elution, and flowthrough from 





Figure 2-4 Serial enrichment of phospho- and phospho(ribosyl)ated peptides out of a complex mixture. 
His-tagged, automodified PARP-1 was denatured in 8M urea and spiked into heavy-labeled whole 
cell lysate from MNNG-treated murine PARG knockout cells before being treated by SVP and then 
digested to peptides and enriched three times in a row on IMAC beads (a).  Samples were taken 
before and after SVP treatment and the His-tagged PARP-1 was separated from the whole cell lysate 
by nickel IP, allowing visualization of the total protein (b), PARylated his-PARP-1 (c), and 
phospho(ribosyl)ated his-PARP-1 (d). MS/MS analysis of the serial enrichments showed that the 
endogenous phospho-peptides and the phospho(ribosyl)ated PARP-1 peptides were depleted from 





Figure 2-5 Proximal phospho(ribosyl)ation sites. 
E488 and E491 are previously characterized PARP-1 automodification sites, shown here in (b) and 
(c), respectively, as compared to the unmodified form of the peptide shown in (a). The doubly 
modified peptide (d) contain diagnostic fragments which carry 1 phosphoribose group (212.01 





Table 2-1 PARP-1 automodification sites identified. 
A total of 20 automodification sites were identified on the PARP-1 standard used for assessing 
phosphoenrichment techniques. 12 of these sites were previously identified and are annotated as 
such here: ˤAltmeyer et al, 2009[16], *Tao et al, 2009 [48], ^Sharifi et al, 2013 [49], ˚Chapman et al, 
2013 [23], ˣZhang et al, 2013 [14]. Those which were identified by Zhang et al are known to be 
endogenous PARylation sites. ZF1 = Zinc Finger 1, ZF2 = Zinc Finger 2, BRCT = BRCA1 C-





Figure 2-6 Phospho(ribosyl)ation on peptide terminal lysine. 
K486, a novel PARP-1 PARylation site identified in our analysis, is shown here at the peptide C-
terminus (b). This fragmentation pattern is compared to that of the unmodified form (a) showing the 
characteristic 212.01 Dalton shift present in the entire y-series, but absent from the b-series, 





Figure 2-7 Endogenous ADP-ribosylation of Arginine. 
In order to identify ADP-ribosylation sites from whole cells we MNNG treated HeLa cells which 
were either heavy (K8R10) or light (K0R0) labeled, affinity enriched ADP-ribosylated proteins, treated 
these proteins with SVP to yield phosphoribose, and then digested these proteins to a peptide 
mixture which would then be enriched either by charged or stripped IMAC beads (a).  Stripped 
IMAC beads from each population would serve as a background control for the reverse labeled 
peptides enriched over a charged matrix.  This example shows the MS (b, c) spectra of both the 
heavy and light form of R4 from Serine/Arginine Rich Splicing Factor 2 (SRSF2), as well as the 




Figure 2-8 The effect of macrodomain enrichment on the (ADP-ribosyl)ated amino acid profile. 
Unique phospho(ribosyl)ated peptides identified from whole cells, as detailed in supplementary table 
2-5, show a shift in the profile of amino acids carrying phospho(ribose) from both human wildtype 





2.8 Supplementary Figures 
 
Supplementary Figure 2-1 Enriching phospho- and phospho(ribose) peptides from a complex background 
 Phospho- and phospho(ribose) peptides were produced from Bovine Casein and SVP-treated 
automodified hPARP-1, respectively. Concurrently heavy-labeled HeLa whole cell lysate was digested 
to generate a background of mostly unmodified peptides from which the standards were mixed into 
and then enriched by either PHOS-Select, GL Sciences or ZirChrom matrices. All digestions utilized 





Supplementary Figure 2-2 Co-enriching phospho(ribosyl)ated peptides by IMAC and MOAC. 
IMAC (PHOS-Select, PS) was compared to MOAC (GL Sciences, GL and ZirChrom, ZC) for 
enrichment of phospho- and phospho(ribose) peptides utilizing a neutral phosphate elution buffer, 
experiment performed in duplicate (Replicates A & B). Unique peptides from each eluate were 
compared (a,b,e,f) and unique peptides from the most promising technique, IMAC (PS), were 
compared to those from the input (unenriched) and flowthrough samples (c,d,g,h). Peptide details 




Supplementary Figure 2-3 PARP-1 is inactivated upon exposure to 8M urea. 
The experimental design depicted in supplementary figure 2-3 shows that the poly(ADP-ribosyl)ated 
standard hPARP-1 is spiked into whole cell lysate following denaturation by 8M urea. Here we have 
shown that denatured hPARP-1 (hPARP-1*) has no poly(ADP-ribosyl)ation activity as shown by a 
failure to automodify in the presence of 32P-NAD. Native sized-unmodified PARP-1 is shown in (a) 
as a band around 120 kD, poly(ADP-ribose) is shown as a smear on the autoradiograph (b) which 





Supplementary Figure 2-4 Multiple PAR sites can exist on the same peptide. 
E488 and E491 are known PARP-1 automodification sites – here they are shown with HCD 
fragmentation (b,c) as compared to the unmodified form (a). Ions which have shifted from the 
unmodified form by the characteristic 212.01 Daltons of phospho(ribose) are marked with a circle. 
The doubly-modified form of the peptide, shown in (d), contains ions seen in the unmodified and 





Supplementary Figure 2-5 Neutral loss sequence from a doubly-modified hPARP-1 peptide. 
This blow-up of the 600-750 m/z window found in Figure 2-4 panel d reveals a neutral loss sequence 





Supplementary Figure 2-6 K350 of HNRNPA1 is phospho(ribosyl)ated. 
Site assignment of the phospho(ribosyl)ated peptide from HNRNPA1 validates the placement of 




2.9 Supplementary Text 
Note on peptide FDRs and score cutoffs:  
Due to the relatively small data sets generated from peptide enrichment a standard FDR (False 
Discovery Rate) of 1% produces an unacceptably high FNR (False Negative Rate)[50]. Therefore 
alternative quality assurance conditions were applied in a parallel MaxQuant analysis where FDRs 
were not considered (set at 1) where scores of 40 and delta scores of 17 were set as a minimum for all 
peptides (MaxQuant 1.4.0.8 default settings use these cutoffs for modified peptides) and all spectra 
used for site identification were manually validated (see Supplementary Spectra). Peptide lists from 
this analysis were used for comparison of phosphoenrichment approaches (see Table 2-1, Figure 2-3 
and Supplementary Figure 2-2). 
Raw Files: 
All raw files are hosted online: www.quantbiology.org/datasets 
Spectra used in figures: 
Spectra used in Figures 2-4 and 2-5 and Supplementary Figures 2-3 and 2-4 were all peptides 
originating from the spiked in “light” PARP-1 standard.  Details: 
Figure 2-4 (CID fragmentation of doubly-modified AEPVEVVAPR): 
 
Figure 2-5 (C-terminal lysine modification): 
 
Supplementary Figure 2-3 (HCD fragmentation of doubly-modified AEPVEVVAPR): 
 
Supplementary Figure 2-4 (Neutral loss sequence from AEPVEVVAPR): 
 
 
Explanation of Supplementary Tables: 
Supplementary Table 2-1: phospho- and phospho(ribose) peptides identified from Casein and 
PARP1 standards, respectively. 
 
Raw file Scan number Modified sequence Charge m/z Fragmentation Mass analyzer Score Delta score
R20130702_cd_2B 7659 _AEPVEVVAPR_ 2 533.79821 CID ITMS 95.483 52.175
R20130702_cd_2B 8092 _AE(pR)PVEVVAPR_ 2 639.8025 CID ITMS 101.38 67.792
R20130702_cd_2B 8963 _AEPVE(pR)VVAPR_ 2 639.8025 CID ITMS 113.44 74.691
R20130702_cd_2B 8941 _AE(pR)PVE(pR)VVAPR_ 2 745.8068 CID ITMS 107.79 43.972
Raw file Scan number Modified sequence Charge m/z Fragmentation Mass analyzer Score Delta score
R20130702_cd_7A 21901 _SLQELFLAHILSPWGAEVK_ 2 1069.5859 CID ITMS 212.74 185.23
R20130702_cd_2B 19264 _SLQELFLAHILSPWGAEVK(pR)_ 2 1175.5902 CID ITMS 194.15 117.39
Raw file Scan number Modified sequence Charge m/z Fragmentation Mass analyzer Score Delta score
R20130702_cd_2B 7658 _AEPVEVVAPR_ 2 533.79821 HCD FTMS 87.895 69.223
R20130702_cd_2B 8091 _AE(pR)PVEVVAPR_ 2 639.8025 HCD FTMS 86.882 70.211
R20130702_cd_2B 8962 _AEPVE(pR)VVAPR_ 2 639.8025 HCD FTMS 86.898 74.979
R20130702_cd_2B 8940 _AE(pR)PVE(pR)VVAPR_ 2 745.8068 HCD FTMS 88.495 60.287
Raw file Scan number Modified sequence Charge m/z Fragmentation Mass analyzer Score Delta score
R20130702_cd_2B 8941 _AE(pR)PVE(pR)VVAPR_ 2 745.8068 CID ITMS 107.79 43.972
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Supplementary Table 2-2: phosphopeptides identified from HeLa whole cell lysate 
 
Supplementary Table 2-3: all proteins identified in this study (excluding reverse & contaminant 
hits) 
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 Poly(ADP-ribose) and mono(ADP-ribose) (collectively: ADP-ribose, ADPr) are post-
translational modifications (PTMs) important in all major cellular processes, poly(ADP-ribose) is 
particularly well known for the critical role it plays in DNA repair, and consequently, cancer. Study of 
this PTM has been limited, however, by a lack of mass spectrometry based proteomic tools for 
identifying the amino acid residues carrying this modification. Recent work from our group and 
others has demonstrated the potential of a tag-based pipeline in which the ADPr monomer or 
polymer is hydrolyzed down to its phosphoribose protein attachment site, leaving a 212 Dalton tag at 
the site of modification. While the pipeline has been proven effective by multiple groups, a barrier to 
application has become evident: the enzyme used to transform ADPr into phosphoribose – snake 
venom phosphodiesterase (SVP) from the rattlesnake Crotalus adamanteus – must be purified from 
venom (no recombinant expression/purification scheme has been shown) and can be tedious to 
isolate away from all contaminating phosphatases and proteases. In this study we outline the steps 
necessary for successfully purifying SVP for use in this pipeline and also present two alternatives to 
SVP, both from the Nudix hydrolase super family: HsNudT16 and EcRppH. Importantly, expression 
and purification schemes for these enzymes have already been proven, with large, high-quality yields 
easily attainable. Here we have demonstrated their utility in identifying ADP-ribosylation sites on 
Poly(ADP-ribose) Polymerase 1 (PARP1) by mass spectrometry and have offered structure-based 
rationale for the ability of these Nudix hydrolases, but not Nudix ADPrases, to degrade protein-
conjugated ADPr. 
3.2 Introduction 
 ADP-ribosylation is a post-translational modification implicated in a number of disease 
states, including cancer, diabetes, and a range of neuropathologies [1]. This protein modification is 
synthesized by ADP-ribosyl transferases, commonly known as PARPs (poly-ADPr-polymerases), 
which transfer the ADP-ribose (ADPr) group from NAD+ to protein acceptor amino acids in 
monomeric (mono(ADPr), MAR) and/or polymeric (poly(ADPr), PAR) form [2, 3]. Identification of 
 
 
specific amino acid acceptors of ADPr, and therefore characterization of the cellular role played by 
this important protein modification, has been hampered by the lack of a robust, universal method for 
both identifying all ADP-ribosylation sites in the proteome as well as individual sites on known 
acceptor proteins. This need has lately been addressed by three different methods, all of which 
involve the digestion or removal of the polymer followed by identification of the ‘tag’ left behind at 
the ADPr conjugation site [4]. One of these methods, digestion of ADPr down to its phosphoribose 
(pR) attachment site, relies upon the pyrophosphatase activity of snake venom phosphodiesterase I 
(SVP) from Crotalus adamanateus, an enzyme which can be purchased in a partially purified form and 
further purified for use against ADP-ribosylated proteins [3, 5, 6]. Unfortunately, this complicated 
purification scheme ultimately results in a high level of prep-to-prep variability, likely due to the 
inherently variable protein source (snake venom) as well as the number of purification steps involved. 
In an effort to identify a more reliable tool for the degradation of protein-conjugated ADPr to 
phosphoribose, we describe here the characterization of candidate enzymes from the Nudix 
hydrolase superfamily. 
 The Nudix hydrolase superfamily catalyzes hydrolysis of Nucleoside Diphosphates linked to 
other moieties (“X”). Most Nudix families contribute to cellular ‘housekeeping’ through the 
breakdown of a wide range of nucleoside diphosphate derivatives [7]. One of these diphosphate 
containing compounds is ADPr [8, 9], a molecule which can accumulate in cells with potentially 
cytotoxic effects by: (1) altering calcium entry into cells via channel gating, thus affecting membrane 
depolarization [10], (2) serving as a neurotransmitter in primate and murine colons [11], and (3)  
spontaneously modifying proteins [12], potentially altering intracellular post-translational signaling. 
Without Nudix hydrolase activity free ADPr would amass during the breakdown of PAR [13, 14], as 
a side product of tRNA synthesis [15], following NAD+ glycohydrolysis [16], following deacetylation 
of O-acetyl-ADPr [17], and through the breakdown of the signaling molecule cyclic ADPr [18]. 
Accordingly, ADPr degrading Nudix enzymes are broadly conserved, with humans possessing at least 
six distinct ADPr pyrophosphatases (ADPrases) [19, 20]. In searching for a Nudix hydrolase 
 
 
substitute for SVP we screened bacterial Nudix hydrolases and identified EcRppH as capable of 
degrading protein conjugated ADPr and thus providing a phosphoribose tag identifiable by mass 
spectrometry. From a structural and biological perspective this finding was intriguing as EcRppH is 
an RNA decapping enzyme, and not an ADPrase [21]. Not long after we made this discovery 
HsNudT16, a human Nudix hydrolase also known to decap RNA [22], was shown to degrade protein 
conjugated MAR and PAR [23]. In this study we provide structure-based rationale for the inability of 
Nudix ADPrases to degrade protein conjugated PAR/MAR, in contrast to Nudix RNA decapping 
enzymes, and demonstrate the use of both EcRppH and HsNudT16 in the identification of protein 
ADP-ribosylation sites by mass spectrometry. 
3.3 Materials and Methods 
Mutagenesis of PARP1 to the E988Q catalytically deficient mutant 
pET28 His-PARP1 was a gift from Dr. John Pascal and served as the template for mutagenesis into 
the mono(ADP-ribose) restricted mutant of PARP1, E988Q. Mutagenesis took placed with the 
following final concentrations: 1x Pfu reaction buffer (Agilent), 0.5 ng/µL pET28 His-PARP1 
template, 2.5 ng/µL primers (Forward: 
GACACCTCTCTACTATATAACCAGTACATTGTCTATGATATTGC, Reverse: 
GCAATATCATAGACAATGTACTGGTTATATAGTAGAGAGGTGTC), 0.2 mM dNTPs (Life 
Technologies), 1 µL of PfuTurbo DNA polymerase (Agilent), the PCR method was as follows: 95⁰C 
for 30 seconds (1 cycle), 95⁰C for 30 seconds/55⁰C for 60 seconds/68⁰C for 17 minutes (12 cycles), 
68⁰C for 51 minutes (1 cycle). The template was digested with 1 µL (10 units) of DpnI restriction 
enzyme (New England Biolabs) for 90 minutes at 37⁰C. 5 µL of the digested DNA was transferred 
to one tube of SoloPack Gold Supercompetent Cells (Stratagene) and incubated on ice for 30 
minutes, placed in a 42⁰C water bath for 30 seconds and then placed on ice for 2 minutes. 250 µL of 
pre-heated SOC medium (Quality Biological) was added to the reaction and incubated for 1 hr at 
 
 
37⁰C shaking at 250 rpm. Cells were plated on LB-Kanamycin plates and incubated at 37⁰C 
overnight. Colonies were sequenced for validation. 
Expression and purification of WT & E988Q HisPARP1 
Method was performed as published previously [5]. 
Purification of SVP 
Method was performed as published previously [5]. Snake venom phosphodiesterase was obtained 
from United States Biological, catalog number P4072, lot number L14030507 C14062702. 
Assessment of contaminating proteolysis activity in SVP prep 
For whole cell lysate (Figure 1e) 1 mg of proteins from HeLa whole cell lysate was denatured in 8M 
Urea (Sigma-Aldrich) 50 mM Tris pH 7 for 10 minutes at 37⁰C before being reduced in 1 mM Tris-
(2-Carboxyethyl)phosphine (Life Technologies) for 10 minutes and then alkylated in 2 mM 2-
chloroacetamide (Sigma-Aldrich) for 10 minutes in the dark. Samples were then diluted to a final 
concentration of 1M Urea, 50 mM NaCl (Sigma-Aldrich), 15 mM MgCl2 (Quality Biological) and 
0.2M Tris pH 7.3. 5 µg of SVP was added to each sample and incubated for 2 hours at 37⁰C. Samples 
were run on an in-house 6-10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Total 
protein was visualized by ProAct membrane stain (Amresco) per the manufacturer’s instructions. For 
purified recombinant His-PARP1, 1 µg of His-PARP1 was automodified as previously published [5] 
and then switched into the same buffer used for the whole cell lysate (above) with or without 1M 
urea. 500 ng of SVP was used for each µg of PARP1 and digestion was carried out at 37⁰C for 2 
hours. Samples were run on in-house 6-10% SDS-PAGE gels and total protein was visualized by 
SimplyBlue Safe Stain (Life Technologies) per the manufacturer’s instructions. 32P-labeled PAR was 
visualized on a phosphor-screen (GE,BAS-III 2040) followed by imaging on a Typhoon FLA7000 
(GE Healthcare Life Sciences).  
 
 
Expression and purification of Nudix hydrolases 
The expression and purification have  been previously published for the following hydrolases: 
EcNudF/ADPRase [20], EcNudE [24], Bd3179/BdNDPSase [25], Dr1184 [26], EcRppH [27], 
AtORF147 and Pa3470 [28]. HsNudT16 was expressed and purified as described in the methods 
from the Structural Genomics Consortium [29]. EcYfcD was purified using the method described for 
EcADPRase [20]. 
Structural analysis of Selected Nudix hydrolases 
Selected Nucleotide sugar hydrolases were use as stereotypes of families according to their published 
preferred substrate ADPr for EcADPRase, TbADPRase, HsADPRase; GDP-mannose for 
EcGDPMK; and BdNDPSase  as a general sugar hydrolase. The structures were structurally aligned 
using SSM and rendered using PyMOL [30]. PAR was constructed and minimized in MOE. For the 
sugar hydrolases PAR was modeled in the active site taking into account the binding preference 
observed in the structures. 
Selected known monomeric Nudix enzymes were structurally aligned using SSM and rendered using 
PyMOL. PAR was modeled in the active site using the mRNA present in NudT16. 
Automodification of WT and E988Q PARP1 
Automodification was performed as published previously [5] with the following changes: both 
wildtype and E988Q PARP1 were incubated with 0.6 µM (0.05 µCi/µL, 1 µCi/sample) 32P-NAD for 
10 minutes at room temperature, following which wildtype PARP1 was incubated with 1 mM NAD 
(non-radioactive) for 10 minutes at room temperature to allow for polymer elongation. 
Digestion of ADPr to phosphoribose 
 
 
5 pmoles of PARP1 wildtype or E988Q mutant were exposed to a hydrolase (various enzymes and 
amounts) in hydrolysis buffer (50 mM Tris pH 7 (Thermo Scientific), 150 mM NaCl (Sigma-Aldrich), 
15 mM MgCl2 (Quality Biological), 1 mM 3-aminobenzamide (Sigma Aldrich) for two hours at 37⁰C. 
Protein digestions for LC-MS/MS analysis 
Proteins were denatured in 8 M Urea (Sigma Aldrich) 50 mM Tris pH 7 for 10 minutes at 37⁰C 
before being reduced in 1 mM Tris-(2-Carboxyethyl)phosphine (Life Technologies) for 10 minutes 
and then alkylated in 2 mM 2-chloroacetamide (Sigma-Aldrich) for 10 minutes in the dark. Samples 
were diluted to: 1M Urea, 50 mM NaCl (Sigma-Aldrich), 15 mM MgCl2 (Quality Biological), 0.2 M 
Tris pH 7 (7.3 at room temperature), and 1 mM CaCl2 (Sigma-Aldrich). LysC (Wako) and Trypsin 
(Promega) were added at in a 1:50 enzyme:substrate ratio. 
Phosphoenrichment of phosphoribosylated peptides 
The ion metal affinity chromatography (IMAC) method described by us in [5] was used. 
LC-MS/MS analysis of phosphoribosylated peptides 
Analysis was performed as in [5]. 
Database search of MS/MS spectra for peptide and protein identification 
Raw files were analyzed by MaxQuant version 1.5.3.8 using protein, peptide and site FDRs of 0.01 
and a score minimum of 40 for modified peptides, 0 for unmodified peptides; delta score minimum 
of 17 for modified peptides, 0 for unmodified peptides. Sequences were searched against an in-house 
database containing the proteins of interest as well as Uniprot Escherichia coli BL21 DE3 database 
(definitions updated October 15th, 2014). MaxQuant search parameters: Variable modifications 
included Oxidation (M), Acetylation (Protein N-term), carbamidomethyl (C), phosphorylation (STY) 
and phosphoribosylation (DEKRC). Max labeled amino acids was 3, max missed cleavages was 2, 




Purification of Phosphodiesterase I from Crotalus adamanteus involves both affinity 
purification and size exclusion chromatography 
 Snake venom phosphodiesterase I (SVP) from Crotalus adamanteus was shown to degrade 
PAR nearly 50 years ago [31] and has since proven a valuable tool for the degradation of PAR into its 
linear, branching and terminal subunits, a technique that yields quantitative information regarding the 
molecular structure of the intact polymer [32, 33]. The utility of this enzyme, however, is greatly 
determined by the purification scheme employed to isolate it from the large number of proteases as 
well as phosphatases and nucleotidases present in the C. adamanteus venom [34]. Oka et al successfully 
isolated the phosphodiesterase activity of commercially available SVP away from the contaminating 
phosphatase and 5’-nucleotidase activity through affinity purification using blue sepharose, a 
molecule which mimics NAD+ and therefore interacts with the active domain of SVP [35]. A 
simplified version of this method used by our group is shown in Fig. 3-1a, where 150 mM Potassium 
Phosphate pH 7.5 is used as a single step elution off of a blue sepharose column. This purification 
scheme paved the way for development of the quantitative method mentioned above but did not 
address the need to eliminate contaminating protease activity. This protease activity can be 
problematic when using SVP to digest protein-conjugated ADPr (e.g. for the purpose of creating a 
phosphoribose ‘tag’ at the otherwise ADP-ribosylated amino acid residue [5, 6, 36]), as we have 
shown in figure 1e wherein a complex mixture of proteins is exposed to blue sepharose purified SVP 
resulting in the degradation of the target proteins and the appearance of SVP along with its co-
purified proteins. This proteolytic activity is further shown against purified, 32P-PARylated PARP1 
(both native and denatured) in Fig. 3-1f. In order to separate the 115 kD SVP from the major 
contaminating proteins (<30 kD) we subjected the blue sepharose purified product to size exclusion 
chromatography, yielding a simple mixture of what are presumably the various glycolytic forms of 
SVP (Fig. 3-1b-d). When tested against 32P-PARylated PARP1 as in Fig. 3-1f this highly pure form of 
SVP displayed phosphodiesterase activity without apparent proteolytic activity (Fig. 3-1g). Similar 
 
 
results were seen against whole cell lysate, allowing for use of this enzyme for protein-conjugated 
ADPr site identification by mass spectrometry [5]. 
 While the pipeline presented here is an effective method for isolating SVP from snake 
venom we believe the complexity of the purification scheme, along with the lot-to-lot variability 
observed from commercial sources which serve as the input for this purification (data not shown), 
could be greatly improved upon by the availability of a recombinant, stable enzyme which could be 
reliably expressed, purified and scaled to meet the often large material demands of proteomic 
pipelines. For this reason we went on to compare the activity of SVP with that of relatively small, 
stable and well characterized Nudix hydrolases, which we hypothesized could cleave protein-
conjugated ADPr with similar specificity. 
Nudix ADPrases do not hydrolyze protein or PAR conjugated ADPr 
 Nudix ADPrases are responsible for the breakdown of free ADPr into its phosphoribose 
and adenosine monophosphate subunits, thus modulating the levels of free ADPr. This knowledge 
lead us to first test a group of Nudix ADPrases for hydrolase activity against protein-conjugated 
MAR and PAR: PARP1, an enzyme known to autoPARylate in the presence of NAD+, was exposed 
to 32P-labeled NAD+ producing either 32P-labeled PARylated (on WT PARP1) or MARylated (on the 
catalytically deficient PARP1 E988Q mutant) proteins to serve as substrates for hydrolysis by 
candidate Nudix enzymes or the positive control, SVP (Fig. 3-2a-c). From a structural perspective, 
the lack of activity towards ADPr could be explained by the dimeric structure of ADPrases, where 
each dimer is formed by monomers of an N-terminal β-sheet domain and a C-terminal Nudix 
domain (Fig 3-2d-g). The N-terminal domains are swapped, creating two active sites where both 
monomers contribute to substrate recognition (for one active site the N-terminal β-sheet of one 
monomer and the C-terminal Nudix domain of the opposite monomer). As shown in Fig 3-2h, 
ADPr is nested in the active site of ADPRase (also known as EcNudF) so that the 1’-hydroxyl of the 
terminal ribose group is completely buried by the protein dimer (white arrowhead), preventing 
 
 
conjugation to another ADPr group (or a protein). This explanation could likely be extended to the 
other three nucleoside sugar hydrolases tested in this study as they display the same quaternary 
arrangement and have a high structural homology with a pairwise root mean square deviation ranging 
from 0.9 to 2.0 Å (Fig 3-2d-g).   
Monomeric Nudix hydrolases are capable of hydrolyzing protein and PAR conjugated ADP-
ribose 
 In order to consider Nudix enzymes with active sites more open to fit the target ADPr 
group bound to either a PAR polymer or protein, we turned to Nudix families which are not 
swapped dimers and lack N- or C-terminal domain insertions, hypothesizing that enzymes with just 
the Nudix fold would have a more open active site. We chose four Nudix enzymes known to be 
monomeric by gel filtration, two of them (Dr1184/CoAse from Deinococcus radiodurans, Fig. 3-3c and 
EcRppH from Escherichia coli, Fig. 3d) degraded the 32P-labeled PAR on the model protein PARP1 
(Fig. 3-3a), while only EcRppH showed slight activity against 32P-labeled MAR (Fig. 3-3b). Structural 
analysis and modeling of EcRppH revealed that the active site within these enzymes could 
accommodate protein conjugated ADPr, as opposed to the ADPrases reported in the previous 
section (Fig. 3-3e-f). 
Both HsNudT16 and EcRppH can degrade protein conjugated PAR and MAR to a 
phosphoribose tag for mass spectrometry 
 A recent study by Palazzo et al [23] has revealed that HsNudT16, a human Nudix 
(deoxy)inosine diphosphatase [37] which is also known to decap small nucleolar RNAs [38] as well as 
cytoplasmic mRNAs [39], has the ability to degrade protein conjugated ADPr. As shown in Fig. 3-4a-
f HsNudT16 has a high structural similarity to both EcRppH and Dr1184 (which showed activity 
against protein conjugated ADPr, see Fig. 3-3a-b) and also possesses an open active site which would 
allow for the target ADPr to be conjugated to a protein or PAR polymer. Based on these similarities 
we postulated that HsNudT16 would have similar activity against protein conjugated ADPr as was 
 
 
observed for EcRppH and Dr1184. To test this 32P-PARylated or MARylated PARP1 was exposed to 
increasing amounts of SVP, EcRppH, Dr1184 or HsNudT16. As shown via autoradiographs in Fig. 
3-4g-h both HsNudT16 and EcRppH are able to remove both forms of ADPr, while Dr1184 showed 
activity against protein conjugated PAR but not MAR.  
To validate that EcRppH and HsNudT16 are degrading ADPr down to its phosphoribose 
attachment site we treated wildtype PARP1 with SVP, EcRppH and HsNudT16 for two hours at 
37⁰C before digesting the proteins to peptides and subjecting them to phosphoenrichment on an 
IMAC matrix, as described by Daniels et al [5]. As shown in Fig. 3-5 all three enzymes (SVP, 
HsNudT16 and EcRppH) degraded ADPr to phosphoribose, allowing for confident identification of 
modification sites by mass spectrometry. 
3.5 Discussion 
 Mass spectrometry-based proteomics represents the gold standard for the study of post-
translational modifications, and the field of ADP-ribosylation will surely benefit from increased 
access to the suite of proteomic tools that have been developed for other PTMs such as 
phosphorylation, acetylation and Ubiquitylation. The advent of tag-based approaches for identifying 
ADP-ribosylation sites has begun to provide access to these tools, but adoption has been relatively 
low due to technical difficulties which accompany the current methods. The work presented here 
promises to streamline an up-and-coming method for ADPr site identification: the simplification of 
ADPr to its phosphoribose attachment. Recombinant HsNudT16 and EcRppH can be synthesized 
and purified from E. coli, allowing for low-cost, high yield production which can be performed in 
most proteomic laboratories. Furthermore, since the structure is known for both of these enzymes, it 
is possible to predict mutations and truncations which could potentially increase the enzyme’s activity 
towards protein conjugated ADPr; for example, introducing mutations which will further open up 
the active site to allow larger ADP-ribosylated substrates access. 
 
 
 The work presented here has the potential to greatly aid in the elucidation of the ADP-
ribosylated proteome by providing researchers the necessary tools for generating phosphoribose as a 
mass spectrometry friendly site localization tag of protein ADP-ribosylation sites.  
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Figure 3-1 Purification of snake venom phosphodiesterase for the digestion of protein-conjugated ADP-ribose 
SVP was first affinity purified on a blue sepharose column (a) followed by size exclusion 
chromatography (b and c), yielding a single ~110 kD band (d). Blue sepharose purification alone 
does not always sufficiently remove protease activity, as shown in (e) where a complex mixture of 
denatured proteins is mostly degraded when exposed to SVP. Panel (f) shows 32P-PARylated PARP1 
being degraded by the same enzyme prep used in (e) in both its native and denatured forms. Panel (g) 
shows the size-exclusion purified SVP degrading the 32P-labeled PAR on PARP1 without any 




Figure 3-2 ADPrases are ineffective against protein-conjugated ADP-ribose. 
(a-c) Autoradiograph showing 32P-labeled mono- or poly(ADP-ribose) conjugated to PARP1 
following exposure to canonical sugar hydrolases: EcNudF, EcYfcD and EcNudE as well as Bd3179. 
For (a) 5 pmoles of PARylated human PARP1 was exposed to 10 pmoles of hydrolase for 2 hrs at 
37⁰C, for (b) 100 pmoles of hydrolases were utilized, while in (c) 5 pmoles of PARP1 E988Q, a 
mutant only capable of synthesizing mono(ADP-ribose), was exposed to 100 pmoles of hydrolases. 
 
 
Ribbon diagrams show the structure of each of the enzymes used: (d) EcNudF/ADPrase (PDB ID 
1KHZ)[20], (e) EcYfcD (PDB ID 2FKB), (f) EcNudE (PDB ID 1VHG) and (g) Bd3179[25]. Panel 
(h) shows a surface representation of EcNudF with modeled PAR polymer based on the complex 
with a nonhydrolyzable ADPr[40]. Panel (i) shows a surface representation of EcNudF with the 
modeled PAR polymer, the inset shows how the terminal ribose is protected and buried within the 






Figure 3-3 Single domain Nudix hydrolases show activity against protein-conjugated PAR. 
(a,b) Autoradiograph showing the 32P-labeled PAR (a) or MAR (b) conjugated to PARP1 following 
exposure to Nudix hydrolases: AtORF147, Pa3470, Dr1184, and EcRppH. In this assay 5 pmoles of 
PARylated PARP1 was exposed to either 20 or 100 pmoles of hydrolase for 2 hrs at 37⁰C. (c) 
Ribbon model of the structure of Dr1184/CoAse (teal, PDB ID 1NQY), (d) Ribbon model of the 
structure of EcRppH (green, PDB ID 4S2Y) with capped RNA bound (green). (e) PAR modeled into 
the active site of EcRppH based on the known orientation of RNA bound in the reported 
structure[41]. Panel f shows a surface representation of EcRppH with PAR conjugated to a protein in 






Figure 3-4 Human Nud16 degrades protein conjugated ADPr. 
Panels (a) and (b) show ribbon diagrams of Dr1184 and EcRppH for comparison. Panel (c) shows a 
ribbon diagram of HsNudT16 (PDB ID 2xSQ), (d) PAR has been modeled into the HsNudT16 
structure with a protein depicted at the conjugation site on ADPr. Panel (e) shows an alignment 
between HsNudT16 and EcRppH, while (f) shows an alignment of HsNudT16, EcRppH and 
Dr1184. Panels (g) and (h) show the removal of 32P-labeled ADPr from 5 pmoles of PARylated (g) or 






Figure 3-5 RppH and Nud16 for the generation of phosphoribose as an ADPr tag for mass spectrometry. 
(a) Phosphoribosylation sites with their corresponding posterior error probabilities identified on 0.05 
nmoles of the model protein PARP1 after the conversion of ADPr to phosphoribose by 0.1 nmoles 
of SVP, 3 nmoles of EcRppH or 3 nmoles of HsNudT16. (b) E491 on PARP1 was identified as a 
PARP1 automodification site following SVP, EcRppH and HsNudT16 treatment. (c) E190 and K192 
were identified as PARP1 automodification sites on PARP1 following EcRppH digestion. (d) 
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 ADP-ribosylation is a post-translational modification where single units (mono-ADP-
ribosylation) or polymeric chains (poly-ADP-ribosylation) of ADP-ribose are conjugated to proteins 
by ADP-ribosyltransferases. This post-translational modification and the ADP-ribosyltransferases 
(also known as PARPs) responsible for its synthesis have been found to play a role in nearly all major 
cellular processes, including DNA repair, transcription, translation, cell signaling and cell death. 
Furthermore, dysregulation of ADP-ribosylation has been linked to diseases including cancers, 
diabetes, neurodegenerative disorders and heart failure, leading to the development of therapeutic 
PARP inhibitors, many of which are currently in clinical trials. The study of this therapeutically 
important modification has recently been bolstered by the application of mass spectrometry-based 
proteomics, arguably the most powerful tool for the unbiased analysis of protein modifications. 
Unfortunately, progress has been hampered by the inherent challenges that stem from the 
physicochemical properties of ADP-ribose which as a post-translational modification is highly 
charged, heterogeneous (linear or branched polymers, as well as monomers), labile, and found on a 
wide range of amino acid acceptors. In this perspective, we discuss the progress that has been made 
in addressing these challenges, including the recent breakthroughs in proteomics techniques to 
identify ADP-ribosylation sites, and future developments to provide a proteome-wide view of the 
many cellular processes regulated by ADP-ribosylation. 
4.2 Introduction 
ADP-ribosylation refers to the transfer of the ADP-ribose group from NAD+ to target 
proteins post-translationally. This post-translational modification (PTM) can be added on to amino 
acids of diverse chemistry, including aspartate, glutamate, lysine, arginine and cysteine. ADP-ribose 
groups can be attached singly as mono(ADP-ribose) (MAR) or in polymeric chains as poly(ADP-
ribose) (PAR) by the enzymatically active members of the family of 17 human ADP-
ribosyltransferases (ARTs), commonly known as poly(ADP-ribose) polymerase (PARPs) [1, 2]. 
Together, MAR and PAR regulate fundamental cellular processes through their roles as signaling 
 
 
molecules [3, 4] and post-translational modifications [5-7]. In addition, ADP-ribosylation has been 
shown to be a therapeutically important modification in cancers, neurodegenerative diseases, 
ischemia and inflammatory disorders [8], where PARPs are hotly pursued drug targets by 
pharmaceutical companies [9]. Over a hundred clinical trials for the treatment of cancers have been 
carried out for PARP1 inhibitors and many ongoing trials are in late stages [10, 11]. Notably, these 
anti-cancer drugs can also cross-react with other PARPs [12], which are increasingly appreciated for 
their multifaceted roles in the cell (Figure 4-1) [6, 13]. Identifying the substrate specificities of these 
PARPs will help elucidate distinct functions of this 17-member family and may have therapeutic 
implications in designing PARP inhibitor-based therapies. Recent advances in mass spectrometry 
(MS)-based methods for characterizing ADP-ribosylated proteins have opened up unprecedented 
possibilities to explore the functions of this family of enzymes and provide insights into the clinical 
relevance of this under-studied protein modification.  
 MS-based proteomics offers three types of data that genomics and transcriptomics cannot: 
protein-protein interaction mapping (interactomics), identification of protein modification sites, and 
quantitative information at the protein level (for an in depth overview of the potential held by MS-
based proteomics we recommend [14]). A complete map of the ADP-ribosylated proteome will 
include all three elements, providing insights into how ADP-ribosylated substrates are regulated via 
recruitment of MAR/PAR-binding proteins, their sites of modification, and abundance in cells. 
While the ADP-ribosylated interactome has been explored in the last decade, it is only recently that 
MS-based techniques have been available for the identification of ADP-ribosylated sites at the 
proteome scale. In this perspective we will explore how MS-based proteomics can help address 
several important questions in the field of ADP-ribosylation: (1) What is the significance of the many 
potential amino acid attachment sites? Which attachments are regulated by which enzymes? (2) How 
can we distinguish between sites of MAR and PAR, and between the many possible structures of 
PAR, including length and branch variants? How important are these distinctions? (3) What does an 
increase in cellular PARylation levels mean? Does it reflect an increase in the number of amino acid 
 
 
site modifications, an increase in the number of ADP-ribose units at existing sites, or an increase in 
unconjugated PAR levels? (4) Are all ADP-ribosylation sites physiologically significant? In the 
following sections, we will discuss the inherent challenges, existing solutions and future needs to 
address these critical questions for a complete, functional understanding of the ADP-ribosylated 
proteome. 
4.3 Investigating the ADP-ribosylated Proteome by Mass Spectrometry: 
Challenges 
Mapping of MARylated and PARylated (collectively, ADP-ribosylated) proteomes requires 
robust protocols to overcome the dynamic, heterogeneous and labile nature of these modifications. 
An initial challenge is the variable PAR attachment sites, which can be found on acidic and basic 
residues, a list that expands when MARylation sites are also considered (see later sections). This 
variability results in a wide range of chemical and enzymatic sensitivities [15], greatly hindering the 
identification of an intact, complete ADP-ribosylated proteome. Secondly, the modification itself is 
typically found at low levels in cells and exhibits very fast attachment/removal kinetics [16, 17], 
making robust enrichment methods a critical component for elucidating the ADP-ribosylated 
proteome. Thirdly, the structure of the PAR polymer poses a practical challenge, as it is 
heterogeneous (between 2 and 200 subunits in vivo, can be branched or linear [18]) and highly 
charged, characteristics incompatible with most MS methods. Here, we will consider the methods 
that have addressed and overcome subsets of these challenges and the potential for further progress 
on those that remain. 
4.4 A Draft of the ADP-ribosylated Interactome 
Molecular interactions can serve as an early indicator of molecular functions, and a sizeable 
contribution has already been made to the field of ADP-ribosylation by several large scale proteomics 
studies that identify proteins associated with MAR and/or PAR which are summarized in Figure 4-2 
panel A [19-22]. These studies used a common experimental design: human cells were exposed to 
DNA damaging agents, a classical stimulant of PARP-1 PARylation activity, before being lysed and 
 
 
subjected to enrichment of ADP-ribosylated proteins, followed by MS-based protein identification. 
Because the enrichment is performed under a range of non-denaturing conditions in all of these 
studies, the proteins identified include not only ADP-ribosylated proteins but also ADP-ribose 
binding proteins and the larger non-covalent interaction networks, thereby providing an aggregate 
picture of the ADP-ribosylated interactome. Using all 832 proteins identified in these studies 
(Supplementary Table 4-2), a draft map of biological processes enriched in the DNA damage-
induced ADP-ribosylated interactome is presented in Figure 4-2 panel B and Supplementary Figure 1 
in detail. While the DNA damage response is the canonical role for PARylation in cells, it is clear that 
additional roles for ADP-ribosylation are present even following genomic insult. In particular, there 
is a significant enrichment of RNA processing factors (purple boxes), a trend which was noted 
individually by each group. Such enrichment may be linked to the similarity of the chemical and 
electrostatic properties of PAR and RNA — cellular biopolymers that are able to share binding 
partners (e.g. [23]). Another noted enrichment is seen for cellular macromolecular complex assembly, 
exemplified in mitotic spindles [24], nucleoli [25], stress granules [26], DNA repair complexes [27], 
and nuclear matrices [28], possibly owing to the polymeric nature of PAR and the plethora of PAR 
binding domains which may target this polymer as a structural scaffold. Such proteome-wide views 
of the biological processes regulated by ADP-ribosylation sends researchers and clinicians a key 
message: a reduction in ADP-ribosylation by PARP inhibitors impacts many aspects of cellular 
function and should not be seen as a simple block to DNA repair. 
In light of the similarities in experimental design, the methods chosen for cell lysis and 
enrichment have proven to be critical determinants of the interactome observed by each group. 
Variations in the enrichment method for ADP-ribosylated proteins produced two nearly distinct sets 
of proteins (see Figure 4-2 panel C), partly resulting from biased affinity of the 10H antibody for 
PAR polymers longer than 20 subunits [29] while the Af1521 macrodomain enriches for both 
MARylated and PARylated proteins [30]. Such biased affinity may help explain why the Af1521 
macrodomain-enriched interactome contains more known ADP-ribosylated substrates (as 
 
 
determined by their inclusion in site identification studies [31, 32]) than the 10H antibody-enriched 
interactome (see Supplementary Figure 4-2), as the longer polymers targeted by the antibody may 
serve as baits for PAR binding proteins and their interactors. The 10H-derived interactome can be 
separated into unique networks based lysis buffer composition (Figure 4-2 panel C), supporting that 
many of these protein-protein and protein-PAR interactors are non-covalent and subject to charge 
disruption. Of note, Nielsen and co-workers emphasized the inclusion of PARP inhibitors in cell 
lysis buffer to prevent the DNA sheared during the cell lysis procedure from activating the DNA 
damage-responsive PARPs in vitro; prevention of this activation cuts down on non-physiological 
PAR-dependent interactions formed in cell lysate [21], an observation that may further explain the 
unique identifications in the studies shown in Figure 4-2 panel C. While these pioneering studies 
highlight the importance for the consideration of lysis conditions and enrichment methods, it is clear 
that we have yet to approach saturation in probing the complete ADP-ribosylated interactome; we 
expect that a more complete interactome will be obtained using complementary strategies to induce 
and enrich ADP-ribose. Besides DNA damage, it is equally important to characterize the ADP-
ribosylated interactomes under other cellular stress as well as the interactomes within various PAR-
enriched cellular macromolecular complexes. Healthy, unstressed cells have also been shown to 
maintain low basal levels of PAR, with cellular PARylation patterns distinct at different stages of the 
cell cycle and in different cellular compartments [13]. Though it is quite common to increase the 
amount of endogenous ADP-ribosylated substrates by long-term knockdown of the PAR degradative 
enzyme PARG, such treatment will likely cause non-physiological changes (as shown in the PARG110 
knockout mouse [33, 34]). While the recent development of cell-permeable PARG inhibitors may 
provide an alternative to increase the amount of substrates without requiring long-term treatment 
[35], it is a priority to improve the existing methods for enriching ADP-ribosylated substrates 
(reviewed in [36]) and increase the sensitivity of MS to detect them from native cell conditions.  
By definition, the ADP-ribosylated interactome is composed of covalently ADP-ribosylated 
substrates, ADP-ribose binding proteins, and their interacting proteins. With the ability to synthesize 
 
 
MAR or PAR with a defined number of ADP-ribose groups [37], it is foreseeable to further refine 
the mapping of the proteome that binds to single or multiple ADP-ribose groups non-covalently. 
Parallel development of techniques to identify the attachment sites of ADP-ribosylation has already 
allowed for definitive identification of ADP-ribosylated substrates at the proteome level ([31, 32]; see 
the next section)). Combination of these complementary sets of proteomic data will allow researchers 
more precision in mapping the connections within the ADP-ribosylated interactome. 
4.5 Characterizing ADP-ribosylation at the Level of the Amino Acid 
Attachment Sites 
While MARylation and PARylation have long been considered two classes of PTMs, it is 
useful, and perhaps more accurate, to consider their attachment sites together as a single 
modification. The first reason for this consideration stems from knowledge of the PAR degradative 
enzyme PARG [38], which is capable of transforming PARylated substrates into MARylated ones, 
effectively blurring the lines between sites of mono and poly(ADP-ribose). Secondly, there is 
evidence of cooperative efforts between enzymes capable of adding mono and poly(ADP-ribose) to 
proteins [39] which may result in a PARP adding polymer to an existing MAR initiation site — an 
occurrence which has also been shown in vitro through PARP-1 elongation of MARylated agarose 
beads [40]. This notion of shared sites for MAR and PAR synthesis is taken further by the 
demonstration that PARP-4 exhibits MARylating activity in isolation but has PARylating activity in 
its native vault protein complex; this change in activity presumably arises through cooperation with 
other members of the complex, none of which are known PARPs [1, 41]. For these reasons, 
characterization of ADP-ribosylation attachment sites remains distinct from characterization of the 
heterogeneous molecule (mono/poly, linear/branched) that occupies these sites. Accordingly, the 
MS-based methods for ADP-ribosylation site identification discussed in this section are restricted to 
identifying the site of the PTM attachment following removal of any subunits beyond the protein-
proximal monomer, offering no information with respect to the original size or structure of the 
corresponding PTM.  
 
 
A major analytical challenge in identifying ADP-ribosylation attachment sites comes from 
the wide variety of amino acids that can be ADP-ribosylated, including glutamic and aspartic acids, 
serines, threonines [42], phosphoserines [43], cysteines [44], asparagines [45], arginines [46], lysines 
[47] and diphthamides [48]. This large collection of ADP-ribose acceptors provides a number of 
unique attachment structures (Figure 4-3) that differ in chemical and enzymatic sensitivities, e.g. 
acidic, but not basic, amino acids lose ADP-ribose in the presence of high pH, hydroxylamine 
quickly releases ADP-ribose groups from modified glutamate, asparatate and, less readily, from 
arginine, and ADP-ribose is exclusively removed from arginine in the presence of the ADPr 
hydrolase ARH1 [15, 49, 50]. Though the majority of ADP-ribosylated sites are sensitive to 
hydroxylamine [51], hydroxylamine-insensitive sites, such as lysine, may also serve important 
biological roles [52]. Phosphorylated tyrosine sites are relatively rare in comparison to phosphoserine 
and phosphothreonine, yet they play indispensable roles in cellular biology [53]; it would be 
important, therefore, to study all intracellular protein residue–ADP-ribose attachments to understand 
the significance of each site of modification. 
 Several sample preparation methods have been developed to study ADP-ribosylation sites by 
MS. The first relies on the unambiguous identification of MARylated sites, which can be identified as 
a 541.06 Dalton mass shift above the unmodified form of the peptide (Figures 4-4 panels A and B). 
A distinct advantage of this method comes from the reliable fragmentation of the modification itself 
during standard peptide fragmentation, providing diagnostic ions that can confirm the ADP-
ribosylation state of the modified peptide [54-56]. This method has also been utilized for the 
identification of PARylation sites following treatment of defined substrates in vitro with PARG or 
ARH3, both of which leave MAR at the otherwise mass variant PAR attachment site [57, 58]. It 
should be noted, however, that an inherent uncertainty underlies a subset of site identifications 
following PARG/ARH3 treatment as these enzymes release free ADP-ribose — a molecule that has 
been shown to spontaneously ADP-ribosylate the N-terminus of proteins and peptides as well as 
lysine and cysteine residues [44, 59, 60]. As such modifications have the potential to form in any 
 
 
environment rich in free ADP-ribose (e.g. in the vicinity of PARG/ARH3 digestion), the occurrence 
and significances of these non-enzymatic modifications in cells remain important unanswered 
questions (see Supplementary Text for further discussion). As such, their presence cannot currently 
be attributed exclusively to either sample preparation or intracellular biology, particularly when 
PARG (or any enzyme capable of producing free ADP-ribose) is present in both scenarios, and the 
field would greatly benefit from performing a series of experiments to clearly establish or dispel 
whether non-enzymatic ADP-ribosylation should be a concern for proteomics studies. 
 Two alternatives have been demonstrated in recent studies to identify ADP-ribosylation sites 
at the proteome level. The first, digestion of MAR and PAR down to their phosphoribose 
attachment sites (Figures 4A and 4C) [32, 61, 62], relies upon the pyrophosphatase activity of snake 
venom phosphodiesterase [63], a standard enzyme for in vitro PAR digestion [64]. Similar to the 
PARG/ARH3 method, the chemistry of the attachment site is maintained, however the iso-ADP-
ribose fragments released by phosphodiesterase do not allow for formation of the reactive aldehyde 
group which has shown to be responsible for spontaneous ADP-ribosylation [60]. The apparent 
unbiased digestion of PAR and MAR by SVP suggests that this method will be amenable to all forms 
of amino acid attachments, and has indeed produced acidic, basic and nucleophilic site identifications 
from endogenously modified proteins [1, 32]. The second method relies upon the release of ADP-
ribose from acidic (glutamic and aspartic) amino acid residues by hydroxylamine, a standard method 
for distinguishing between amino acid acceptors of ADP-ribose [15]. The utility of this method lies 
in the alteration of the acidic group following hydroxylamine release of ADP-ribose (Figure 4A); the 
resultant hydroxamic acid derivative produces a mass shift of 15.01 Daltons, which is easily 
distinguishable by MS (Figure 4D) [31]. Though limited to identifying only acidic ADP-ribosylation 
sites, this method has provided a list of 1,048 sites on 340 proteins from the acidic ADP-ribosylated 




With the ability to definitively identify ADP-ribosylation sites, it is now possible to begin 
addressing the roles of protein ADP-ribosylation. The functional impact of such modified sites can, 
to some extent, be addressed by mutagenesis studies using recombinant proteins or by targeted 
genome editing techniques in cells. However, unique difficulties accompany these classic means of 
characterizing PTM effects, as point mutations are limited by the large number of amino acids that 
can be ADP-ribosylated (Figure 4-3). For example, mutation of a glutamic acid to an aspartic acid 
will not guarantee a lack of ADP-ribosylation, requiring researchers to, in the interest of blocking 
ADP-ribosylation, mutate acidic sites to non-acidic residues. The requirement of such mutagenesis 
strategies further complicates the interpretation of molecular or cellular effects — is ADP-
ribosylation of the residue important, or has the loss of an acidic residue changed the structure or 
interaction network of the protein? As an alternative to blocking ADP-ribosylation by mutational 
means, chemical strategies have been developed to introduce ADP-ribose groups at specific residues 
on purified peptides [65-67]; this technique could allow researchers to mimic the ADP-ribosylated 
form of a protein by conjugating the modified peptide of interest to the terminus/termini of the 
parent protein, a technique (termed semisynthesis) which has allowed for functional analysis of 
phosphorylated proteins in vitro [68]. Another way to ascertain functional roles of these sites 
involves following their modification status temporally upon treatment that induces or inhibits ADP-
ribosylation. For example, quantitative proteomics techniques have already been utilized to map out 
the temporal coordination of ADP-ribose related protein complexes in response to DNA damage, a 
necessary step toward understanding the mechanism of ADP-ribose dependent DNA damage repair 
[20, 22]. With these newly developed site identification techniques we can further define the temporal 
changes of the ADP-ribosylated substrates at the site level, potentially indicating which particular 
sites are of physiological significance. Additionally, it has been shown that only a subset of ADP-
ribosylation sites within the proteome are sensitive to treatment by chemotherapeutic PARP 
inhibitors currently in Phase III clinical trials [31]. These variable responses to PARP inhibition may 
 
 
indicate the mechanism of action of these drugs, providing the molecular basis of the clinical benefits 
and side effects observed in patients.  
4.6 Defining Target Specificity for Addition and Removal of ADP-
ribosylation 
Given the large number of cellular processes regulated by PARPs (see Figure 1), it will be 
interesting to determine the shared and unique substrates of each of the enzymatically-active family 
members. Using a protein microarray that consists of 8,000 proteins, two groups have identified the 
sub-proteomes that can be modified by PARP-2, PARP-10 and PARP-14 in vitro [69, 70]. 
Alternatively, the Cohen group has engineered PARP-1 and PARP-2 mutants that specifically use a 
bio-orthogonal NAD+ analogue for the identification of their respective PARP-specific substrates 
from nuclear extracts in vitro [71]. The majority of proteins modified by individual PARPs are distinct, 
suggesting that each PARP exhibits unique substrate specificity (Figure 4-5, Supplementary Table 4-
3). When coupled with site identification techniques, it is now possible to determine if there is a 
defined motif surrounding the ADP-ribosylation sites modified by each PARP. For example, whether 
any of the PARPs are responsible for the consensus sequence of PXE*, E*P, PXXE or E*XXG 
surrounding the modified glutamate (E*) residue, as identified by the Yu group recently [31]. Similar 
experimental designs may allow us to deduce whether there are specific motifs for modification by 
individual PARPs, such as those identified for PARP-5a substrates [72].  
One puzzling piece of data from the current studies is that ADP-ribosylation sites auto-
modified by each PARP are found at diverse amino acids, such as acidic (Glu/Asp), basic (Lys, Arg) 
and nucleophilic (Cys) residues; this apparent lack of specificity is true for PARPs that add multiple 
(PARP-1) or single ADP-ribose groups (PARP-3, PARP-6, PARP-10, PARP-11, PARP-12 and 
PARP-16) [1, 32]. This flexibility in amino-acid acceptor residues argues against the amino acid 
specificity of these enzymes, at least during in vitro auto-modification. One possible explanation is 
that these PARPs are acting as NADases, which hydrolyze NAD+ in vitro [73], and the released 
ADP-ribose groups chemically conjugate to reactive amino acid residues. Though no studies have yet 
 
 
to investigate such non-enzymatic modification on PARPs, Cervantes-Laurean et al showed that 
histones can be modified non-enzymatically by incubation with ADP-ribose in vitro and deduced that 
lysines are the primary sites [60]. On the other hand, only cysteine residues were identified in auto-
modified PARP-8 in vitro, suggesting that certain PARPs may have defined amino acid specificity [1]. 
It will therefore be of interest to examine whether there are any amino acid preferences on 
endogenous protein substrates of each PARP at a proteome-wide scale. One major drawback of the 
current techniques to identify proteome-wide enzyme–substrate relationships is that these 
experiments were all performed in vitro, thus losing the proper physiological context (e.g., cellular 
localization, enzyme concentration, protein modification states). Therefore, techniques are urgently 
needed to identify PARP-specific proteomes in cells. 
So far, hydrolases that remove the single ADP-ribose groups from arginine and glutamate 
have been identified (Table 4-1), but it is not clear whether modifications at other amino acids are 
reversible. Do hydrolases exhibit amino acid specificity with regard to ADP-ribose removal? 
Similarly, would the biological modules that bind ADP-ribose groups, such as a macrodomain, have 
substrate or amino acid binding specificity? Notably, the specificities of macrodomains have been 
shown to be dependent on the amino acids surrounding the modified sites [66, 74]. Thus, these 
macrodomains will likely enrich for a restricted set of endogenous ADP-ribosylated proteins. 
Recently, by comparing the ADP-ribosylated proteome from human and mouse cells before and 
after enrichment by the Af1521 macrodomain, our group found that the macrodomain-enriched 
proteome selects against ADP-ribosylated glutamate residues globally [32], consistent with the earlier 
findings that this macrodomain bears hydrolase activity against acidic MARylated amino acids of a 
single substrate [7, 75]. It can be postulated, then, that the glutamate sites identified following 
enrichment by Af1521 macrodomain were PARylated prior to enrichment, as MAR would have been 
hydrolyzed off. Using this same line of reasoning, binding and hydrolase specificity (for both the 
targeted ADP-ribosylated residues and neighboring amino acids) of all ADP-ribose binding modules 
can be systematically defined. Table 4-1 summarizes the binding affinity and substrate specificity of 
 
 
some of the most-studied ADP-ribose binding domains and hydrolases. While the primary aim of 
these characterization studies is often to elucidate the role these protein domains play in cell biology, 
they have also provided a much-needed expansion of a ‘biological toolbox’ for distinguishing 
between classes of ADP-ribosylated substrates, an effort which began 20 years ago with the ARH1-
aided classification of substrates carrying MARylation on arginine residues [76]. This toolbox should 
provide the means for enriching targeted groups of ADP-ribosylated proteins to expand our 
knowledge of the ADP-ribosylated proteome. 
4.7 Distinguishing between sites of MAR- and PARylation 
While it is advisable — and at this point only possible — to study the attachment sites of all 
forms of ADP-ribosylation together, the distinction between MAR and PAR, as well as the many 
subclasses of PAR, will likely prove critical for interpretation of the role played by the modified 
residue of interest. For example, five out of the 15 enzymatically active human PARPs are 
responsible for PARylation activity, with the other 10 restricted to MARylation (Figure 4-1), meaning 
that a change in the PARylation status of a residue can only be attributed to the enzymatic activity of 
those five PARPs. A similar analysis could be employed for the ADP-ribosyl hydrolases: two can 
only remove MAR (macroD1 and macroD2), two can turn PAR into MAR (PARG and ARH3) and 
one can remove both PAR and MAR (TARG1; see table 4-1) [77]. Therefore, understanding how an 
ADP-ribosylation site is changing between an unmodified state and carrying MAR or PAR can 
suggest the enzymes responsible for its regulation. The clinical implications of understanding the 
distinction between PAR vs. MAR is exemplified in the PARP inhibitor classification performed by 
Wahlberg et al., where 185 PARP inhibitors were assayed for their abilities to bind members of the 
human PARP family; many of these inhibitors bind to MARylating as well as PARylating members of 
the family [12]. Such potential off-target inhibition of MARylation would not be revealed by the 
typical assay for monitoring the effectiveness of PARP inhibitors, which only measures changes in 
PARylation level. Knowing which ADP-ribosylation sites are affected by these inhibitors (or in 
disease states) and how those ADP-ribosylation sites are changing between unmodified, MARylated 
 
 
and PARylated will be predictive of the PARPs targeted in cells. Finally, multiple ADP-ribose groups 
in PAR may define functional roles distinct from MAR. For example, while wild-type, PARylation-
capable PARP-1 is able to fully rescue DNA repair in PARP-1-/- MEFs, a PARP-1 mutant that is 
only capable of MARylation activity cannot [16]. Such detrimental changes brought on by converting 
PARylation to MARylation sites may be because the structure of PAR is similar to that of polynucleic 
acids (e.g. DNA) and thus could compete for, or modulate the functions of, factors that bind nucleic 
acids. For these reasons, we will now examine potential methods for classifying sites of ADP-
ribosylation based on the structure of their PTM. 
As diagrammed in Figure 4-4B, MAR is a homogenous modification with a predictable mass 
of 541.06 Daltons, allowing MARylation site localization by MS. Given that MARylated peptides can 
be captured by phosphopeptide enrichment techniques [78], it is feasible to globally enrich 
MARylated peptides from protease-digested cell lysates. In fact, re-analysis of phosphoproteomic 
data uncovered 79 MARylated proteins [79]. However, this re-analysis likely underestimates the 
global level of MARylation due to the high pH (pH 10) phosphopeptide elution employed [80], a 
condition which results in loss of ADP-ribose groups conjugated to acidic sites [15]. Consistently, all 
but one of the MARylated sites identified in the re-analysis were arginine, an observation which was 
partly attributed to the increased stability of ADP-ribosylated arginine as opposed to ADP-
ribosylated glutamate in the conditions employed for their study [79]. For non-biased detection of 
MARylated proteomes, the labile bond between ADP-ribose groups and acidic amino acids must be 
preserved, e.g. by choosing a neutral phosphate buffer for eluting the phosphopeptide enrichment 
matrices (as in [32]). 
Another possibility to distinguish MARylated substrates from PARylated substrates is to 
exploit the distinct properties of protein domains that specifically recognize them (see biological 
toolbox, Table 4-1). For example, the WWE domain recognizes iso-ADP-ribose — the molecular 
structure spanning consecutive ADP-ribose subunits of PAR [81]; therefore this domain could be an 
 
 
ideal tool for enriching PARylated, but not MARylated, targets. Alternatively, MacroD2 can be 
engineered to abrogate its inherent ADP-ribose hydrolase activity but retain its binding specificity 
towards MARylated substrates [75]. However, most of these domains were tested with single 
MARylated or PARylated substrates. Use of this biological toolbox for proteome-wide investigation 
warrants systematic analyses of these ADP-ribose binding modules to fully characterize their 
substrate specificities for both binding and hydrolysis. 
4.8 Free/Conjugated, Branched/Linear: the many forms of Poly(ADP-
ribose) 
Besides identifying the ADP-ribosylation sites, MS can also be used to accurately quantitate 
PAR levels with femtomole sensitivity [82]. Assuming an average chain length of 10 ADP-ribose 
units per PAR molecule, the Bürkle group estimated that there are about 3,000 PAR molecules/cell 
in native cellular conditions, which can be induced to >150,000 molecules/cell upon DNA damage, 
with a branching frequency of 1–2% [82]. Combining this methodology with site identification could 
allow researchers to deduce whether the increase in PARylation is a result of new PARylation sites 
and/or substrates, or simply elongation of existing sites on existing substrates. However, one should 
be aware of an alternative source of PAR — the soluble PAR that is not attached to target proteins. 
The existence of soluble PAR in vivo has been inferred from mounting evidence that PARG has both 
endo- and exo-glycosidic activity, allowing this enzyme to produce and regulate levels of free PAR 
[77]. Additionally the ADP-ribosyl hydrolase TARG1 has been shown to reduce PARylation levels 
on auto-modified PARP-1 without releasing free ADP-ribose in vitro [83], indicating that the entire 
PAR chain could be released as a single unit in cells. The cellular implications of free PAR were 
demonstrated by the release of apoptosis-inducing factor (AIF) following exposure of cells to free 
PAR, an effect which was not observed in the presence of digested PAR [84]. Finally, the ADP-
ribosyl hydrolase ARH3, which degrades PAR, regulates the release of AIF in cells, hypothetically 
through its ability to degrade free PAR [85]. Notably, cellular PAR levels are an important clinical 
parameter to measure the effectiveness of PARP inhibitors and/or chemotherapeutic agents in 
 
 
clinical trials (as in NCI standard operating procedure #340505) as well as a predictive biomarker 
proposed for PARP inhibitor sensitivity [86, 87]. An understanding of the conjugation state of 
cellular PAR is necessary for accurate interpretation of changing PARylation levels.  
Current approaches do not account for another important parameter — the structural 
subclasses of PAR. These subclasses include length variants [1, 2] as well as branching variants 
(PARPs 1 and 2 make branched polymers while 5a makes linear polymers [88-90]). These differences 
could functionally impact PAR’s role as a scaffold, where different lengths of the polymer have 
already been shown to recruit distinct populations of proteins (e.g. [91]) — a potential mechanism 
for temporal coordination of cellular processes [92, 93]. The development of proteomic tools to 
determine polymer length and structure in cells could shed light on the unique roles played by the 
many forms of PAR. The recent development of a purification scheme for large amounts of PAR 
standards of defined length [37] could potentially pave the way for characterizing the length of the 
polymer on PARylated substrates. Ultimately, the goal is to use MS to simultaneously identify both 
the sites of ADP-ribosylation and the number of ADP-ribose groups that are attached to those 
modified sites. Such technical challenges bear remarkable similarity to the problem of the site-specific 
microheterogeneity observed in N-linked glycosylation, where structures of sugar polymer attached 
to the modified sites could be of different lengths and varied degrees of branching [94]. Recent 
advances in search algorithms have been able to map simultaneously the glycosylation sites, the 
number of sugar moieties and the branch points of the sugar polymer attached at the modified site of 
single proteins [95]. Though an ADP-ribose moiety carries more negative charge and generally two-
fold more mass than sugar moieties, it is perhaps feasible to map both the modified sites and short 
oligomers (<15mers) attached on single PARylated proteins in the future.  
4.9 Assessing the physiological relevance of ADP-ribosylation sites 
4.9.1 Site Occupancy 
Complete characterization of a single ADP-ribosylation site will include accurate 
identification of four factors: (1) amino acid conjugation site, (2) enzymes responsible for addition 
 
 
and removal of the modification, (3) structural make-up of the modification (mono? poly? 
branched?), and (4) site occupancy/stoichiometry. While progress has been made in the first three 
endeavors as discussed above, it is the last aim which will most aid in the determination of 
functionally and physiologically relevant sites of ADP-ribosylation; functional (and therefore 
regulated) sites will likely exhibit a defined stoichiometric change in response to stimulus, while non-
functional sites will show no change or changes that cannot be associated consistently with the 
biological stimulus applied. Quantifying a change in site occupancy, however, is much more 
challenging than quantifying a change in protein levels as the measurement may track the changing 
intensity of a single peptide as opposed to many peptides from a single protein [96]. Additionally 
many of the modifications may exist at very low stoichiometries, making quantification extra sensitive 
to variability introduced during sample preparation, a challenge which has been mitigated by the use 
of internal, stable-isotope labeled standards [97, 98]. Investigation of site occupancies (and the 
identification of robust, reproducible changes at determined sites) has the potential to test two 
hypotheses: (1) that some protein/peptide N-terminal, lysine, arginine, and cysteine modifications 
may be non-functional (and therefore represent biological noise), as they have the potential to be 
formed non-enzymatically by ADP-ribose groups that are released from PAR degradation by 
PARG/ARH3 and/or NADase activity of PARPs [44, 59, 60] and (2) that ADP-ribosylation of 
proteins is not always residue-specific, and may occasionally be mapped to a protein region as 
opposed to an amino acid. This latter hypothesis has been proposed to explain PARP-1 PARylation 
of BRCA1, wherein regions of BRCA1 were identified as PARylation acceptors as opposed to sites 
[99]. This observation stands in contrast to PARP-1 mediated PARylation of the tumor suppressor 
p53, of which mutational analysis has yielded three p53 PARylation sites that account for nearly all of 
the PARylation present on the substrate [100]. Mutating all three residues to alanine resulted in 
cytoplasmic accumulation of p53 and further biochemical experiments indicated that this site-specific 
PARylation on p53 blocked its interaction with the nuclear export receptor Crm1 [100]. Both region-
specific as well as site-specific mechanisms appear to be at play following PARP-1 auto-modification, 
 
 
an event which has been carefully characterized by a number of MS studies in recent years, resulting 
in a large number of site identifications (see Figure 4-6, source data in Supplementary Table 4-4) [31, 
32, 55, 62, 83]. While several defined modification sites such as E488 and E491 have been identified 
by all studies there are also regions -- such as the C-terminus of the WGR domain stretching from 
E642-E650 -- which show regional, but not necessarily site-specific, overlap between studies. The 
ability to monitor whether sites or protein regions exhibit the regulatory patterns associated with 
cellular changes will provide essential data for determining their relative importance. 
4.9.2 Top-down Proteomics 
A necessary step forward will come from linking ADP-ribosylation into the established 
network of integrated PTMs [101]. Some work has already been done to link PARylation and 
ubiquitination [102], as well as ADP-ribosylation and acetylation [103], elucidating important cellular 
mechanisms. Future findings will be brought on by the constant development of MS analysis 
software, a critical component in PTM identification, as well as the increasing availability of liquid 
chromatography methods and mass analyzers that are compatible with top-down proteomics. As top-
down proteomics analyzes intact proteins (rather than the peptides which result from proteolysis), 
this method can often distinguish between protein proteoforms, i.e. gene products that are post-
translationally processed in multiple ways, often with functional implications [104, 105]. This 
technique has proven powerful in the analysis of complex proteoforms such as histone variants, 
enabling the simultaneous characterization of the 14 H2A proteoforms [106], and more recently, 
whole-protein kinetics of acetylation turnover on histones H3, H4 and H2A [107]. In the same way, 
top-down proteomics could facilitate the identification of groups of temporally or spatially correlated 
ADP-ribosylation sites, as well as other protein modifications. Integration of ADP-ribosylation into 
the growing network of PTMs has the potential to reveal novel regulatory roles for ADP-ribosylation 




The power to monitor and interpret proteome-wide changes in ADP-ribosylation states 
promises to advance the fundamental understanding of ADP-ribosylation biology and facilitate 
further connections between cellular and patient responses to therapeutic PARP inhibition. The 
depth of the proteome will clearly be advanced with the invention of better tools to enrich ADP-
ribosylated proteomes — MAR/PAR-binding proteomes, MAR/PARylated proteomes and PARP-
specific proteomes from cells in different cellular conditions, particularly native conditions which are 
understudied due to their low levels of ADP-ribosylation. However, such procurement of vast 
amounts of data must be coupled with the urgency to address basic questions such as whether the 
site of the PTM attachment matters, whether the PTM is always added enzymatically, and what the 
functional consequences are of adding single vs. multiple ADP-ribose residues onto the attachment 
site. In light of the promise shown by these new proteomic tools for the study of ADP-ribosylation, 
it is high time to investigate this therapeutically important, yet enigmatic, protein modification at a 
detailed mechanistic level.  
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Figure 4-1 The PARP family 
PARPs have been linked to nearly all major cellular processes. Juxtaposition of protein identifiers 
(e.g. 1 = PARP-1) indicates the involvement of the protein in the regulation or execution of the 
cellular process. Enzymatic activity is indicated by the bubble color: blue = poly(ADP-
ribosyl)transferase, red = mono(ADP-ribosyl)transferase, green = no transferase activity. For 





Figure 4-2 Processes enriched in the ADP-ribosylated interactome 
(A) Experimental design for the interactome studies used for this meta-analysis. (B) A compilation of 
the proteins identified in response to DNA damage can be broken out by enrichment methods (bait) 
or cell lysis conditions. For comparison of lysis conditions the 10H enriched proteins were 
compared. Euler diagrams created in VennMaster [3, 108]. (C) The pooled DNA-damaged induced 
ADP-ribosylated interactome depicted as a treemap of enriched biological processes. The most 
enriched biological processes (based on statistical likelihood) are shown as larger components within 
the map, and grouped according to common cellular functions. Gene ontology determined using 
DAVID [109], treemap constructed using REViGO [110] and R [111]. PARGi, PARG inhibitor; 




Figure 4-3 ADP-ribosylation attachment sites 
Known and predicted structures linking amino acids to ADP-ribose, grayed out boxes show 





Figure 4-4 ADP-ribosylation tags 
(A) Poly(ADP-ribose) can be simplified to mono(ADP-ribose) as in (B) by the glycohydrolase activity 
of PARG/ARH3, (C) to phosphoribose through digestion by phosphodiesterase, or (D) to a 
hydroxamic acid derivative though exposure to hydroxylamine. Of note, hydroxylamine treatment on 
ADP-ribosylated arginine results in the formation of the hydroxymate of ADP-ribose [50] and 
 
 
therefore will likely not leave the 15.01 Da signature on formerly modified arginine residues as in 




Figure 4-5 PARP Substrate Specificity 
Substrates for PARP-1, PARP-2, PARP-10 and PARP-14 were identified in three studies using 
protein arrays or analogue sensitive mutant protein identification (see text). Euler diagrams created in 





Figure 4-6 PARP-1 automodification sites 
Schematic of PARP-1 includes protein domains and secondary structure; α helices are shown in red, 
β sheets in yellow. Auto-modification sites identified by at least two independent studies are shown. 
Size of annotated residues based on number of independent research groups which have identified 
the modification site. E488 and E491 located at the C-terminus of the BRCT domain are identified 
by all MS studies are shown as the two major auto-modification sites. For references see text and 







Table 4-1 A biological toolbox of ADP-ribose binding and hydrolysis protein domains 
Our current understanding of the most well-studied ADP-ribose binding domains and hydrolases. 
Green = Yes, Red = No, E/R = hydrolysis shown specifically for glutamic acid or arginine residues, 
respectively. MD = macrodomain, N/A = not applicable, blank = possible but currently unknown. 
SARS-CoV, Severe Acute Respiratory Syndrome-Coronavirus; HEV, Hepatitis E Virus; SFV, Semliki 
Forest Virus. 
References:1[7, 75, 112], 2[30, 113], 3&4[114, 115], 5[7, 30, 32], 6[7, 75, 115], 7[7, 115], 8&9[7, 74], 10[116-





4.13 Supplementary Figures 
 
Supplementary Figure 4-1 Processes enriched in the ADP-ribosylated interactome (full table of Figure 2B). 
Gene ontology determined using DAVID, treemap constructed using REViGO and R. Source data 





Supplementary Figure 4-2 Comparing the ADP-ribosylated interactomes with the known ADP-ribosylated 
proteomes. 
PARGi, PARG inhibitor; PARPi, PARP inhibitor; PARGkd, PARG knockdown. Interactome 
studies, including protein extraction and enrichment conditions, are described in detail in Figure 2A. 




4.14 Supplementary Text 
A cautionary note—the possibility of non-enzymatic ADP-ribosylation  
Non-enzymatic modification of amino acids by ADP-ribose has been identified by several pioneers 
in the field, including studies by Drs. Elaine and Myron Jacobson (e.g. Cervantes-Laurean et al., 
1996), Joel Moss (e.g. McDonald and Moss, 1994), and mentioned in reviews by Drs. Alexander 
Bürkle (Bürkle, 2005), Guy Poirier (D'Amours et al., 1999) and Michael Hottiger (Hassa et al., 2006). 
These original studies clearly indicated the possibility for ADP-ribose to non-enzymatically conjugate 
to lysine, arginine and cysteine residues in vitro, using different analytical tools, including NMR, 
chromatography profile, and sensitivities to different chemicals. As stated in Cervantes-Laurean et al., 
1996, the chemical conjugation of ADP-ribose (also known as glycation) was added to proteins in a 
concentration-dependent manner and can occur even within 8 minutes (the shortest timepoint 
sampled). Figure 5 in this 1996 paper further illustrated different rates of chemical ADP-ribosylation 
for different histones that have different numbers of lysines (e.g. H1 with 56 lysines incorporated less 
than H4 with 11 lysines), suggesting that the incorporation may not be random. Drawing a parallel to 
non-enzymatic glycation by glucose, only specific lysine residues in albumin are chemically 
conjugated in vivo (Iberg and Flückiger, 1986), therefore it is not clear whether each lysine is equally 
non-enzymatically modified.  
Given the highly sensitive nature of state-of-the-art mass spectrometry, the stable nature of ADP-
ribose-lysine/arginine bond and the use of enrichment tools to identify ADP-ribosylated sites, it is 
experimentally feasible to detect even low level of artificial “noise” from biological samples prepared 
for proteomics studies. We would like to note that ADP-ribose can be generated by (1) 
PARG/ARH3 conversion of PARylation sites to MARylation sites for site identification and/or 
potentially in vivo (Messner et al., 2010; Rosenthal et al., 2011), or (2) PARPs when acting as 
NADases (e.g., Desmarais et al., 1991). In addition, ADP-ribose has been used as an elution 
condition for macrodomain enrichment for ADP-ribosylated proteins (Dani et al., 2009), which 
would not be a problem in identifying substrates; however, the excessive amount of free ADP-ribose 
 
 
used for elution could potentially chemically conjugate the substrates in the eluates in vitro, resulting 
in the identification of non-physiological ADP-ribosylation sites by mass spectrometry. Given that 
the effect of chemical conjugation by ADP-ribose in proteomic studies remains uncertain, the field 
would greatly benefit from performing a series of experiments to clearly establish whether or not 
non-enzymatic ADP-ribosylation should be a concern for proteomics studies.  
Criteria for proteomics datasets analyzed in Supplementary Table 2 
We have analyzed all four proteomic studies undertaken so far that identify ADP-ribosylated 
substrates along with their interactors (i.e., the ADP-ribosylated interactome) (Gagné et al., 2008; 
2012; Isabelle et al., 2012; Jungmichel et al., 2013). We note that the Jungmichel et al 2013 study is 
aimed at mapping ADP-ribosylated targets (substrates) during DNA damage. However, based on the 
materials and methods in Jungmichel et al (2013), PAR enrichment was performed in cell lysis buffer 
containing 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.05% sodium 
deoxycholate, protease inhibitors, phosphatase inhibitors, PARG inhibitor and PARP inhibitor. This 
buffer most closely resembles the modified RIPA buffer commonly used in proteomics for protein–
protein interactome enrichment (e.g. by the Matthias’ Mann group in Ong and Mann, 2006) , though 
contains less of the ionic detergent which represents the harshest denaturant in the buffer (0.05% 
sodium deoxycholate vs. 0.25% in Ong and Mann, 2006). Standard RIPA buffer, which contains 1% 
sodium deoxycholate, is also commonly employed for the study of protein-protein interactions 
(Sefton, 2001). Therefore, conservatively, it can reasonably be assumed that the proteins identified in 
this study constitute ADP-ribosylated interactome, i.e. ADP-ribosylated proteins, ADP-ribose 
interactors, and protein¬–protein interaction partners of both the former and latter. However, we 
noted that the lysis conditions used are slightly more stringent than those used by Poirier and co-
workers in their 2008 and 2012 studies as summarized in Figure 2A (Gagné et al., 2008; 2012; Isabelle 
et al., 2012). Using the current set of 384 ADP-ribosylated substrates with defined sites mapped 
(Daniels et al., 2014; Zhang et al., 2013), 82 of these proteins overlap with the Jungmichel 2013 data, 
 
 
accounting for ~35% of their Af1521 macrodomain-enriched proteome. On the other hand, there 
are 28 proteins overlapping with the Gagné 2012 data, accounting for a comparable ~33% of their 
Af1521 macrodomain-enriched proteome (see Supplementary Figure 2 below). The differences in 
induction, lysis and enrichment conditions, cell lines as well as limited sampling, in general, could all 
contribute to the different degrees of overlap. The actual proportion of ADP-ribosylated substrates 
vs. binding proteins found in these respective studies can be determined with approaches that 
identify specific sites of ADP-ribosylation in future studies. Given that the condition reported in 
Jungmichel et al (2013) cannot exclude the inclusion of proteins that binds to ADP-ribosylated 
substrates, we therefore take a conservative approach and discuss the paper in the context among 
other pioneering works of ADP-ribosylated interactomes. 
In order to control the many variables present in the meta-analysis presented in Figure 2B, the 
proteins identified through PARG-dead enrichment were omitted, as they represent a single dataset, 
whereas the 10H (Gagné et al., 2008; 2012; Isabelle et al., 2012) and macrodomain (Gagné et al., 





4.15 Supplementary Tables 
 
Table S1. Functions attributed to PARP family members.  
Supporting examples from the literature for the connection made between each PARP and each 
cellular process in Figure 1. 
 
Table S2. The ADP-ribose interactome 
Sourced data used to generate the ADP-ribosylated interactomes shown in Figure 2. See 
Supplementary Text for criteria of data inclusion. 
 
Table S3. PARP specific substrates 
Sourced data used to generate the Euler diagrams showing PARP-1, PARP-2, PARP-10 and PARP-
14 specific substrates in Figure 5. 
 
Table S4. Auto-modification sites identified on PARP-1 
Sourced data used to generate the PARP-1 auto-modification site map from Figure 6. 
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5 Conclusions and Future Directions 
 Our work has produced an MS based pipeline for identifying ADP-ribosylation sites on 
proteins, as outlined in Figure 5-1. We have demonstrated the potential for this method through the 
identification of modification sites on endogenously MARylated and PARylated proteins (see 
Chapter 2) at both acidic and basic amino acid residues, suggesting an unbiased means of detection. 
The prospects for future development and application of this pipeline are presented in this chapter.  
5.1 Future Development - Exploring the ADP-ribosylated proteome to a 
greater depth 
 Our survey of the endogenous ADP-ribosylated proteome (see Chapter 2) identified 63 
ADP-ribosylated residues from 21 human proteins and 33 murine proteins. A similar study using an 
alternative technique identified 1,048 acidic ADP-ribosylation sites on 340 human proteins [1], as this 
method is blind to all non-acidic protein conjugation events, and we uncovered a roughly equal 
number of acidic (31) and basic (32) site identifications, it can be reasonably assumed that the depth 
of the entire ADP-ribosylated proteome is substantially more than either study reported. In an effort 
to make our own protocol more robust, and thus capable of identifying more ADP-ribosylation sites 
from the same protein mixture, we have searched for an alternative enzyme for hydrolyzing protein-
conjugated ADP-ribose to phosphoribose. Snake Venom Phosphodiesterase (SVP) – the 
pyrophosphatase used by our group – must be purified from snake venom (a recombinant 
purification scheme has not been reported) resulting in a multi-step purification process that is both 
cumbersome and produces lot-to-lot variability in the final product (see Chapter 3). Nudix enzymes 
represent an alternative class of hydrolases (including ADPrases) which, contrary to SVP, has been 
structurally and mechanistically characterized [2-4]. Our systematic screen of bacterial nudix 
hydrolases identified RppH from Escherichia coli as a pyrophosphatase capable of cleaving protein-
conjugated ADPr to phosphoribose, albeit approximately 10x less efficiently than SVP (see Chapter 
3). This activity could potentially be amplified by protein engineering, producing a robust tool for the 




 Engineering enzymes to modify substrate specificity or activity typically relies upon 
mutagenesis, either through rational design, directed evolution, or semi-rational design. The first, 
rational design, involves mutating discrete residues based on knowledge of the protein structure and 
catalytic mechanism [5]. The second, directed evolution, follows the process of natural selection in 
that it subjects a gene to iterative rounds of random mutation and selection [6]. As this process is 
random, knowledge of the protein structure or functional mechanism is not necessary, however a 
rapid screening process would be imperative to implementing this method, typically one which does 
not include purification of the expressed protein (the read-out can occur within cells or cell lysate). 
Semi-rational design exists as a compromise between rational design and directed evolution: critical 
regions of an enzyme (typically those surrounding the active site) are subjected to random 
mutagenesis and screened for the desired change in activity, thus obviating the need for a detailed 
mechanistic understanding of the protein function but making use of available structural information 
[7]. Considering the X-ray structure of substrate(RNA)-bound and free RppH has recently been 
solved [8] it is feasible to attempt rational design for the purpose of altering the substrate specificity 
of RppH, thus increasing the enzyme’s pyrophosphatase activity against protein-conjugated ADPr.  
 An alternative to rational design for increasing RppH ADPr pyrophosphatase activity is to 
immobilize RppH to a matrix, a technique which has been shown to increase activity through 
buffering of local and global pH in a reaction mixture [9]. This buffering occurs due to decreased 
diffusion rates around the enzyme-conjugated matrix, allowing the researcher to equilibrate the 
matrix in the preferred pH for the enzyme prior to exposing the matrix to the substrate-compatible 
buffered reaction mixture. As enzymes often have a very narrow pH range for optimal activity (in the 
case of RppH the range is from pH 8.5-9.0 [10]) this buffering could be quite valuable for processing 
ADP-ribosylated substrates which must be kept at or below pH 7 in order to maintain all protein 
modifications (see Chapter 3).  
 Our screen began with the nudix ADPrases, as we rationalized that enzymes capable of 
hydrolyzing free ADPr would also be capable of degrading protein conjugated ADPr, a hypothesis 
 
 
that we were unable to prove true (see Chapter 3). Structural analysis revealed that the active sites for 
these enzymes were highly restricted, largely due to their dimeric nature, in which both monomers 
contribute to substrate binding and specificity (see Figure 3-2). Circular permutation (the re-
arrangement of protein domains, thus perturbing tertiary, and occasionally quaternary, structure [11]), 
then, could be a way to abolish dimerization of these enzymes (as has been done for the human 
protein β-Crystallin and the bacterial protein Cyanovirin-N [12, 13]), thus opening up the active site 
for protein conjugated ADPr. 
5.2 Future Applications 
5.2.1 Characterizing protein acceptors of ADP-ribose 
 Protein ADP-ribosylation has been implicated in a number of clinically and biologically 
important cellular pathways, several of which have been diagrammed in Figure 5-2. Identification of 
the ADP-ribosylation sites on these substrates has so far been laborious and time-consuming, often 
requiring multiple rounds of mutagenesis and activity assays to identify candidate conjugation sites. A 
successful example of this is the identification of E255, D256 and E268 on p53 as ADPr acceptor 
residues [14], site identification by mutagenesis is rarely so simple with ADP-ribosylation, however, 
as can be seen from similar attempts on PARP1 [15, 16] and BRCA1 [17]. Mass spectrometry based 
approaches from our group (this thesis) and Zhang et al. [1] have substantially increased the number 
of known protein ADP-ribosylation sites, though a brief comparison with Figure 5-2 reveals the non-
saturating nature of these approaches: Zhang et al. identified E2043 as an ADP-ribosylation site on 
the tail of Numa1, our group identified K350 as an ADPr acceptor on HNRNPA1 (see 
Supplementary Figure 2-6 and Figure 5-3), all other substrates (including p53) were not characterized 
by either of these methods. Substrate characterization, then, may require a targeted approach (e.g. 
through the use of recombinant, tagged forms of the substrate of interest which can then be 
enriched) as well as site validation through mutagenesis. 
 
 
5.2.2 Identifying critical changes in the ADP-ribosylated proteome 
 As covered in Chapter 1, PARP inhibitors are an important class of therapeutic drugs used 
(or undergoing clinical trial) for cancer treatment, with potential for application in: neurotrauma, 
neurodegenerative diseases, autoimmune diseases, and myocardial infarction (see Figures 1-4 and 1-
5). As a molecularly targeted chemotherapeutic, it is rational to consider the activation state of the 
cellular processes affected by inhibition of PARP when selecting patients and tumor types as well as 
appropriate adjuvant and neoadjuvant therapies. Accordingly, researchers have long considered the 
state of DNA damage repair and overall PARylation levels when predicting PARP inhibitor 
sensitivity and/or choosing complementary therapies (see Figure 5-4). These conjectures are based 
on the knowledge that automodification of PARP1 and PARP2 (often considered the primary targets 
of PARP inhibitors) plays a role in DNA damage repair; therefore an increase in global PARylation is 
predictive of high levels of DNA damage repair and thus PARPi sensitivity. This overly simplistic 
model has guided PARP inhibitor development over the last ten years, ultimately resulting in FDA 
approval of the PARP inhibitor Olaparib for use by patients with BRCA mutant ovarian cancer [18]. 
Future development of these inhibitors, particularly outside of the realm of adjuvant DNA damage, 
will require a more precise understanding of cellular PARylation levels. For example, an increase in 
cellular PARylation could be due to changing levels of protein conjugated PAR or free PAR; 
elongation of existing PARylation sites or PARylation of new proteins. Distinguishing between these 
scenarios could separate out the effects exerted by unique PARP inhibitors (for example those which 
inhibit PARP5a and 5b versus those that inhibit PARP1 and 2), identifying cellular environments as 
appropriate targets. The pipeline described in this thesis has the potential to not only characterize the 
changing PARylation state at the level of the amino acid, but will also detect MARylation, a PTM 
which is also regulated by PARP inhibitors but otherwise invisible to the ADPr antibodies currently 
available. This new understanding of protein ADP-ribosylation could allow researchers to recognize 
molecular patterns predictive of disease progression and PARPi sensitivity/resistance. Ultimately, 
robust biomarkers could be identified as a simple and reliable readout for clinical applications. 
 
 
5.2.3 Searching for biomarkers of disease, treatment and drug resistance. 
 As discussed above, cells deficient in DNA damage repair (particularly homologous 
recombination) are considered good candidates for PARPi treatment, and this understanding has led 
to the large majority of PARPi clinical trials being designed by either (1) co-treating patients with 
DNA damaging agents such as ionizing radiation or alkylating agents or (2) enrolling patients with 
presumably defective DNA repair based on genetic analysis. The most successful genetic biomarkers 
employed in this scenario are BRCA1 and BRCA2, both critical components of homologous 
recombination that are part of the two-hit model of PARP sensitivity: losing BRCA and PARP 
together is much more cytotoxic than the loss of one alone. As biomarkers, however, BRCA 
mutations have limits: BRCA mutated tumors can acquire resistance to PARP inhibitors [19], patients 
with breast or ovarian cancer that lacks BRCA mutations can respond to PARP inhibitors [20, 21], 
and only 15% of high-grade epithelial ovarian cancers and 20% of triple-negative breast cancers (the 
two most PARPi responsive cancer types) carry BRCA mutations [22, 23]. There is a need, then, for 
a more robust marker for PARPi sensitivity. Considering the activity targeted by PARPi is the PTM 
ADP-ribosylation it is worth looking for ADP-ribosylated substrates in this context. 
 The observation of increased levels of PARP and PARylation has already prompted 
researchers to suggest PARPi for the treatment of non-cancerous disease states: PARP1 antibodies 
have been detected in the sera of patients with the autoimmune disorders: lupus, rheumatoid 
arthritis, scleroderma, Sjögren’s syndrome, pulmonary fibrosis, sarcoid, ulcerative colitis, and Crohn’s 
disease [24, 25], and general up-regulation of cellular protein PARylation has been detected in the 
neurodegenerative disorders Alzheimer’s [26], amyotrophic lateral sclerosis [27] and Parkinson’s (in 
which PARP1 expression is elevated [28]). As discussed in the previous section, however, broad 
observations of increased PARylation levels are poor indicators of molecular changes at the level of 
cellular pathways and processes. Identifying the contextual alterations in protein ADP-ribosylation 
with single amino acid resolution would allow researchers to begin the search for novel PARPi 
sensitivity biomarkers, as well as markers of disease progression.  
 
 
5.3 Final Thoughts 
 The study of protein ADP-ribosylation has much to offer both basic and translational 
science: it is an intriguing PTM that manages to modify more amino acid residues than any other 
known PTM, it appears to have multiple means of regulating proteins through its highly charged 
polymeric presence, as well as what seems to sometimes be a regional (not site) specific protein 
modification. Despite over 50 years of research, scientists do not fully understand or agree upon the 
clinically and biologically significant mechanism of PARP1 automodification. Despite these 
challenges, great strides (and one great stumble [29]) have been made in the realm of 
chemotherapeutic PARP inhibitors, opening doors for real and significant impact on the lives of 
patients. In 2005 the ADP-ribosylation field learned that cancer cells harboring mutations in the 
breast cancer genes BRCA1 or BRCA2 were highly sensitive to PARP inhibition, less than 10 years 
later the first FDA approved PARP inhibitor appeared in cancer clinics for BRCA mutation positive 
ovarian cancer patients. Considering the vast progress that has been made recently in the study of 
ADP-ribosylation, not least the connections being made by our group and others to the mass 
spectrometry field, it is not unreasonable to look forward to the next great discovery that will propel 
PARP inhibitors forward, this time along with the insight gained from a fundamental understanding 






Figure 5-1 Pipeline for identifying ADP-ribosylation sites. 
Protein-conjugated ADP-ribose (mono and poly) are hydrolyzed to phosphoribose, an SDS page gel 
shows the protein reaction occurring on a model substrate (total protein, in red, was visualized by 
coomassie blue staining, phosphoproteins, in green, were visualized using the Pro-Q Diamond kit 
from invitrogen). Phosphoribosylated protein is digested to peptides and phosphoribosylated 
peptides are enriched on a positively charged matrix (in this depiction, Iron(III) IMAC resin is used). 
Enriched peptides are competitively eluted by excess phosphate, allowing for target peptides to be 






Figure 5-2 Snapshots showing protein ADP-ribosylation in cellular pathways.  
NER  = Nucleotide Excision Repair, NHEJ = Non-Homologous End Joining, PARP = Poly(ADP-
ribose) Polymerase, PARG = Poly(ADP-ribose) Glycohydrolase, Numa1 = Nuclear mitotic 
apparatus protein 1, Crm1 = Exportin1/XPO1, NFĸB = Nuclear Factor kappaB, XRCC = X-ray 
Repair Cross-Complementing Protein 4, UV-damaged DNA Binding Protein, DNA-dependent 
Protein Kinase, catalytic subunit. *pathway observed in Drosophila melanogaster, hrp38’s human 
homologue is HNRNPA1, hrp40 is an HNRNP protein (no direct homologue). Drosophila only has 
one PARP.  





Figure 5-3 A historical perspective on research into ADP-ribosylation of HNRNPA1 
We identified K350 as an endogenous ADP-ribosylation site on HNRNPA1 (see Chapter 2), adding 







Figure 5-4 Combination therapies maximize PARPi potential as a chemotherapeutic agent. 
Clinical trials are ongoing that employ combination therapies to enhance the cytotoxicity of PARP 
inhibitors. Most of these complementary therapies fall into one of seven categories: HRR deficient 
(the patient carries this status due to loss or mutation of an HRR protein, including the BRCA 
proteins)[44], Taxanes (which block mitosis through the suppression of microtubule dynamics)[45], 
Nucleoside Analogues (which are erroneously incorporated into DNA, blocking transcription) [46], 
DNA Crosslinking [47], Radiation [48, 49], DNA Alkylating Agents [50], or Topoisomerase I 
inhibition (wherein Topo I can no longer repair the nick it made while releasing torsional stress) [51]. 
For many of these therapies the benefits of PARP inhibition can be at least partly attributed to the 
 
 
loss of the high-fidelity SSB repair pathways BER and NER or the stimulation of the low-fidelity 
DSB repair pathway NHEJ [52-54]. In the case of Taxanes and Nucleoside Analogues, however, 
DNA repair is not expected to play a direct role in their sensitization, leaving the mechanism of 
synergistic cytotoxicity unknown. BER = Base Excision Repair, HR = Homologous Recombination, 
NHEJ = Non-Homologous End Joining, SSB = Single Stranded Break, DSB = Double Stranded 
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6 Characterizing phosphorylation on MacroD2 
 
6.1 Abstract 
 In an effort to develop the protein MacroD2 as a tool for distinguishing between sites of 
mono- and poly(ADP-ribose) (see chapter 4) we have identified a series of phosphorylation sites on 
the C-terminus of MacroD2, a protein which was otherwise not known to be phosphorylated. The 
site stoichiometry of these phosphorylation sites is increased on mutant forms of MacroD2 which 
are unable to bind and/or hydrolyze ADPr, suggesting a functional role for phosphorylation on 
MacroD2. Further studies are warranted to determine the roles these phosphorylation sites place in 
MacroD2 localization, function and cellular role. 
6.2 Introduction 
 Complete characterization of a protein ADP-ribosylation event will ultimately require 
knowledge of the amino acid conjugation site, the occupancy of this conjugation site, and the 
structure of the modification itself (mono/poly, linear/branched) – an idea presented and defended 
in Chapter 4 of this thesis. To this end, we have proposed using ADP-ribose binding proteins (or 
their domains) to distinguish between mono- and poly(ADP-ribosyl)ated proteins by way of their 
specificity for binding and/or removing one, but not the other, of these modifications. In our 
analysis of all ADPr binding domains (see Table 3-1) macroD2 stood out to us as a potential tool for 
enriching mono-, but not poly-, ADP-ribosylated proteins and/or peptides for identification by mass 
spectrometry. Specifically, this enzyme was shown to bind and remove mono(ADP-ribose) from 
acidic residues, activities which could be modulated by the introduction of single point mutations [1] 
– these mutations would thus allow researchers to robustly distinguish between MacroD2 interaction 
partners which are dependent upon the macrodomain binding to ADPr and those which are 
interacting with MacroD2 independent of its ADPr-binding abilities. In this appendix we have begun 
 
 
to characterize MacroD2 and its functionally deficient mutants (binding and/or hydrolase deficient) 
for the purpose of their application as tools for distinguishing between sites of mono- and 
poly(ADP-ribose). Serendipitously, however, we have found a swath of phosphorylation sites on the 
C-terminus of full-length macroD2, a protein which was not previously known to be phosphorylated. 
Furthermore, we have shown that phosphorylation site occupancy (relative to the unoccupied, ie 
unmodified, state of the amino acid site) increases for the ADPr binding and/or hydrolase deficient 
mutants of macroD2 as compared to the wildtype. 
6.3 Materials and Methods 
Expression and purification of HisPARP-1  
See section 2.3. 
Purification of Snake Venom Phosphodiesterase I (SVP) 
See section 2.3. Snake venom phosphodiesterase was obtained from United States Biological, catalog 
number P4072, lot number L14030507 C14062702. 
Preparing oligos for in vitro PARP-1 activation 
See section 2.3. 
Automodification of E988Q HisPARP-1 in vitro.  
See section 2.3. 
Cell Culture 
HeLa cells were grown in the presence of heavy-isotope labeled arginine and lysine before PAR 
induction by N-methyl-N'-nitro-N-nitrosoguanidine, as in Chapter 2, page (update). Freestyle 293-F 
cells (Invitrogen) were cultured per manufacturer’s recommendations. GFP-MacroD2 (as obtained 
from Dr. Andreas Ladurner[2]) was transfected into Freestyle 293-F cells using Lipofectamine-2000 
following the manufacturer’s protocol (1 ug of construct per 1e6 cells).  
Immunoprecipitation of GFP-MacroD2 
GFP-MacroD2 transfected 293-F cells were washed with ice-cold PBS and lysed in 1x mRIPA buffer  
(50 mM Tris pH 7.5, 150 mM NaCl, 1% n-Octyl Glucoside, 1 mM EDTA, 1x SigmaFast Protease 
 
 
inhibitor, and 0.1% sodium deoxycholate) on ice for 10 minutes. Lysate was cleared by centrifugation 
and added to pre-equilibrated GFP-Trap beads (from ChromoTek) in mRIPA buffer, 80 uL of 
slurry/65 mL of cells. 
Affinity purification of mono(ADP-ribosyl)ated substrates 
20 µg of GFP-MacroD2 (wildtype, binding mutant G100E or hydrolase mutant 
G100E/I189R/Y190N) on GFP-Trap beads was exposed to 5 µg of automodified PARP-1 E988Q 
and 500 µg of heavy-labeled, DNA damaged HeLa whole cell lysate in wash buffer (1M Urea, 200 
mM Tris pH 7, 150 mM NaCl, 15 mM MgCl2,1% n-Octyl Glucoside) for 30 minutes at room 
temperature. Samples were washed three times with wash buffer and denatured in 8M Urea (in 50 
mM Tris pH 7) at 37⁰C for 10 minutes before being reduced in 1 mM Tris-(2-
Carboxyethyl)phosphine (Life Technologies) for 10 minutes and then alkylated in 2 mM 2-
chloroacetamide (Sigma) for 10 minutes in the dark. 
In-solution protein digestion 
See section 2.3. 
Phosphoenriching phosphorylated, ADP-ribosylated and phospho(ribosyl)ated peptides 
See section 2.3. 
NanoLC-MS/MS analysis 
See section 2.3. 
Database search of MS/MS spectra for peptide & protein identification 
See section 2.3, with the following changes: MaxQuant version 1.5.2.8, human Uniprot FASTA 
database updated Dec. 2nd, 2014.  
6.4 Results 
Identification of the wildtype and mutant interactomes 
 GFP-MacroD2 wildtype as well as binding and hydrolase mutants were expressed and 
purified from human 293-F cells. As shown previously[1], the point mutation G100E abolishes 
ADPr binding and hydrolysis (hereafter referred to as the ‘binding mutant’), while the point 
 
 
mutations I189R and Y190N together restore ADPr binding without restoring ADPr hydrolysis, thus 
providing the ‘hydrolase mutant’ used in this study (Figure 6-1). These proteins were then exposed to 
heavy (K8R10) labeled HeLa cell lysate to identify the unique interaction network accompanying each 
protein. Stable interactors, or those which were maintained from the GFP-IP, were distinguished by 
their light (K0R0) labeling state, while those newly acquired from the HeLa cell lysate carried heavy-
labeled amino acids (see Figure 6-2). Mono(ADP-ribosyl)ated (MARylated) human PARP-1 E988Q 
was included as an ADPr-conjugated protein standard to ascertain the relative ADPr binding and 
hydrolase activity of the MacroD2 mutants with respect to wildtype. ADPr site identification was 
aided through the digestion of ADPr to phosphoribose by the enzyme snake venom 
phosphodiesterase and the subsequent enrichment of phospho(ribosyl)ated as well as phosphorylated 
peptides by immobilized metal affinity chromatography (IMAC) (for a detailed explanation of this 
pipeline see Chapter 2). Unfortunately no quality spectra showing PARP1 E988Q ADPr or 
phosphoribose sites were identified, and therefore ADPr enrichment and site identification by this 
method requires further study and will not be considered for this thesis appendix. 
MacroD2 is highly phosphorylated and this phosphorylation is affected by modulation of 
ADPr-binding and hydrolase activities 
 Following GFP-MacroD2 exposure to heavy-labeled HeLa whole cell lysate the wildtype and 
mutant proteins were digested to peptides and phosphopeptides and phosphoenriched by IMAC. 
This phosphoenrichment produced four phosphopeptides from MacroD2 (Figure 6-3, panel A) 
which were identified in multiple states, including the unmodified forms found in the flowthrough 
(Figure 6-3 panel B). Both the phosphorylated and nonphosphorylated forms of the peptides 
occasionally showed methionine oxidation, a post-translational modification which is often seen as 
an artifact attributed to mass spectrometry sample processing, and will be considered such in this 
case (Figure 6-3 panel B). In order to examine the change in phosphorylation state between the 
wildtype and mutant forms of MacroD2 the phosphorylation occupancy of each phosphopeptide 
was compared, as in Figure 6-3 panel C. Briefly, the total ion current (TIC) read out from an LC-MS 
 
 
analysis includes looking at the m/z ratios of all eluting peptides along with their corresponding 
intensities and retention times. In order to compare intensities of a single peptide across runs, 
however, the TIC is filtered to only display the m/z ratio of the peptide of interest, this is referred to 
as an extracted ion current, or XIC, and is shown in Figure 6-3 panel C for phosphopeptide #1 in 
this study. The intensities of these peaks are derived from the area under the curves and are 
considered an indication of the abundance of the peptide of interest (which is definitively identified 
through MS/MS fragmentation, known retention time, and the m/z ratio of the intact peptide). In 
this way the abundance of each form of the peptides of interest is determined and these abundances 
are compared across samples to ascertain changes in phosphorylation occupancy on the peptide of 
interest, the result of which is shown in Figure 6-3 panels D-H for phosphopeptides 1-4. In the case 
of all four peptides the phosphorylation occupancy increases for the ADPr binding and hydrolase 
mutants as compared to wildtype. 
MacroD2 may be phosphorylated by Casein Kinase 1α 
 As phosphorylation occupancy increased for the peptides of interest from both ADPr 
binding and ADPr hydrolysis deficient MacroD2 mutants we hypothesized that the increased 
phosphorylation may be a result of increased interaction with a protein kinase by the mutant proteins 
as compared to the wildtype protein. Accordingly we examined those proteins which were identified 
as interactors for the mutant proteins while not identified in the wildtype MacroD2 interactome 
(Figure 6-4 panel A). Of the serine/threonine kinases identified (cyclin-dependent kinase 2, casein 
kinase 1α, integrin-linked protein kinase) only one, casein kinase 1α, was found to have a target motif 
matching the MacroD2 phosphorylation sites identified, specifically either [pS/pT]X1-2[S/T] or 
[D/E]nX1-2[S/T] (Figure 6-4 panel B)[3, 4].  
6.5 Discussion 
 This pilot study has provided evidence that phosphorylation may play a role in MacroD2 
function, and most importantly has identified novel phosphorylation sites on MacroD2, including: 
S276/T284/T285 (ambiguous), T390, S400, S401, T406, S415, T424 and S426 (see supplementary 
 
 
spectra). The functional role of these phosphorylation events has yet to be determined, and should 
be addressed in future studies. Considering the variation in phosphorylation states between wildtype 
and mutant MacroD2 proteins it may be best to use the macrodomain of MacroD2 as bait for ADP-
ribosylated proteins, thus removing the bias these phosphorylation events may impose between 
wildtype and mutant forms of MacroD2. 
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Figure 6-1 MacroD2 mutations modulate ADPr binding and hydrolysis 
As discovered by Jankevicius et al in 2013[1], the MacroD2 point mutation G100E abolishes ADPr 
binding and hydrolysis by MacroD2, while the I189R and Y190N mutations (in combination) 




Figure 6-2 Acquiring the interaction network of MacroD2 wildype and mutant proteins. 
GFP-MacroD2 proteins were expressed and purified from human light-labeled 293-F cells before 
being used as bait against a mixture of whole cell lysate (heavy, human, HeLa cells) and in vitro 





Figure 6-3 Binding and hydrolase deficient mutants of MacroD2 are more highly phosphorylated than wildtype. 
Analysis by mass spectrometry revealed four phosphopeptides from MacroD2, labeled here as 
phosphopeptides 1-4 (A), three of which were found in multiple post-translationally modified states 
(B). The extracted ion current (XIC) for each peptidic form was collected as in (C) and plotted as the 
percent total intensity for each peptide, ie the phosphorylation site occupancy (D-H). In the case of 
 
 
phosphopeptide #2 (E) the only form identified was singly phosphorylated, and therefore the 






Figure 6-4 Casein Kinase 1α may be responsible for the increased phosphorylation of the mutant MacroD2 
proteins. 
In order to procure a list of potential kinases responsible for the change in phosphorylation of 
MacroD2 the protein interactors were identified, particularly the kinases found to be enriched by the 
mutant, but not wildtype, forms of MacroD2 (A). The two bona fide Serine/Threonine kinases 
identified in this group were casein kinase 1α (CK1α) and and cyclin-dependent kinase 2 (cdk2). The 

















1. Jankevicius, G., et al., A family of macrodomain proteins reverses cellular 
mono-ADP-ribosylation. Nat Struct Mol Biol, 2013. 20(4): p. 508-14. 
2. Timinszky, G., et al., A macrodomain-containing histone rearranges 
chromatin upon sensing PARP1 activation. Nat Struct Mol Biol, 2009. 
16(9): p. 923-9. 
3. Flotow, H., et al., Phosphate groups as substrate determinants for casein 
kinase I action. J Biol Chem, 1990. 265(24): p. 14264-9. 
4. Flotow, H. and P.J. Roach, Role of acidic residues as substrate 











Primary Contact Info: 
cs.dnls@gmail.com 
17801 Bowie Mill Road 
Derwood, MD 20855 




Casey M. Daniels 
Johns Hopkins Bloomberg  
School of Public Health 
cmdaniel@jhsph.edu 
615 N Wolfe St E8647 
Baltimore, MD 21205 
410-614-1355 
  
Scan for LinkedIn profile: 
EDUCATION: 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
PhD Candidate, 2010 - Present 
 
University of Maryland, Baltimore County, Baltimore, MD 
Bachelor of Science, Biological Sciences, 2006 – 2010 
 
LABORATORY EXPERIENCE: 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 2010 - 
Present 
Department of Biochemistry & Molecular Biology, Advisor: Dr. Anthony Leung 
PhD Candidate 
Project: Poly(ADP-ribose), or PAR, is a cellular polymer implicated in DNA/RNA 
metabolism, cell death, and cellular stress response via its role as a post-translational 
modification. The nature of these PAR polymers (large, charged, heterogeneous, 
base-labile) has made its amino acid attachment sites difficult to study by mass 
spectrometry. My thesis work has produced a pipeline which allows for the 
enrichment and identification of (ADP-ribosyl)ation sites via the enzymatic product 
of phosphodiesterase-treated ADP-ribose, phospho(ribose).  My current focus is on 
characterizing the mono- and poly(ADP-ribosyl)ated proteome by application of this 
novel technique, the result of which would represent the first unbiased (by amino 
acid attachment-site) look into this important proteome. 
 
University of Washington, Seattle, WA Fall of 2012 
Department of Pharmacology, Advisor: Dr. Shao-En Ong 
Visiting PhD Student 
Project: To support my current thesis project (see above) I spent 7 weeks training in 
the field of proteomics under the mentorship of Dr. Shao-En Ong, an expert in 
phosphoproteomics and a pioneer in the field of SILAC. 
 
University of Maryland, Baltimore County, Baltimore, MD 2009-2010 
Department of Chemistry & Biochemistry, Mentor: Dr. James Fishbein 
Research Assistant 
Project: N-nitrosomorpholine (NMOR) is a potent carcinogen and mutagen, formed 
by the reaction of morpholine (a cheap, commercially available chemical) with 
sodium nitrite (found in the human body) in acidic media.  Metabolism of NMOR 
occurs in the liver by P-450 enzymes and is consequently a proponent of liver 
cancer, along with esophageal and nasal tumors.  My project centered around 
 
 
studying the effects of NMOR intermediates on DNA, hypothesizing its 
spontaneous decomposition and further potential to form crosslinks via nucleoside 
adducts. 
 
Wyeth (Pfizer) Pharmaceuticals, Collegeville, PA Summer of 2008 
Department of Nuclear Receptors and Dermatology, Mentor: Dr. Catherine 
Thompson 
Research Intern 
Project: Explored the role of Liver X Receptor beta (LXRβ) in mouse epidermis to 
determine whether LXRβ is a therapeutic target for improving the integrity and 
function of aged skin. A member of the nuclear receptor superfamily, LXRβ is a 
transcription factor that regulates specific genes in response to ligand binding. LXRβ 
is highly expressed in the skin, and LXR ligands induce the expression of genes that 
are important for skin function, such as those that regulate lipid metabolism. 
 
University of Maryland, School of Medicine, Baltimore, MD 2007 - 2008 
Department of Pharmacology and Experimental Therapeutics, Advisor: Dr. Angelika 
Burger (dec.) 
Research Assistant 
Project:  Tested the efficacy of the analogue 2’-F-ara-deoxyuridine (a cancer therapy 
drug currently in pre-clinical trials) as a suicide prodrug when used on cell lines from 
malignant human lung, breast and colon tumors which were grown in mice. 
 
Siegfried Pharmaceuticals, Pennsville, NJ Summer of 2007 




2014 - 2015 The Elsa Orent Keiles Fellowship in Biochemistry 
The Johns Hopkins Bloomberg School of Public Health 
 
2006 – 2010 Academic Enhancement Award 
University of Maryland, Baltimore County 
 
2007 & 2009 Semester Academic Honors 
University of Maryland, Baltimore County 
 
2007  Dean’s List 
University of Maryland, Baltimore County 
 
2007  President’s Award 






 2014 Undergraduate Student Advisor 
  Student: Lingga Adidharma 
  Contact: ladidharm@gmail.com, 1-307-460-8236 
 
 2014 PhD Rotation Student Advisor 
  Student: Pola Olczak 
  Contact: polaolczak7@gmail.com, 1-443-683-7059 
 
 2015 PhD Rotation Student Advisor 
  Student: Robert (Lyle) McPherson 
  Contact: rmchpher5@jhu.edu, 1-847-715-6811 
   
RESEARCH GRANTS: 
 11/2014 – 5/2015 Joy Cappel Young Investigator Award, Rockland    
    Immunochemicals 
    $4000 
 
 4/2014   Travel Award, Johns Hopkins Bloomberg School of Public Health  
    Student Assembly 
    Applied to “PARP Family & Friends” Conference 
    $350 
 
 4/2014   Travel Award, Cold Spring Harbor Laboratory 
    Applied to “PARP Family & Friends” Conference 
    $100 
 
 7/2013   Tuition Assistance, Cold Spring Harbor Laboratory 
    Applied to CSHL Proteomics Training Course 
    $750 
 
 7/2011 – 6/2013 Training Grant 5 T32-CA009110-35 (PI: Miller), National Cancer  
    Institute 
    Training in Areas Fundamental to Cancer Research 
    Full Stipend Support 
 
 10/2012 – 12/2012 Travelling Fellowship TF261, Journal of Cell Science 
    Supported training with Dr. Shao-En Ong in Seattle, WA 






“The Promise of Proteomics for the Study of ADP-ribosylation” 
Casey M. Daniels, Shao-En Ong, Anthony K.L. Leung 
Molecular Cell 2015 58 (6), 911-924 
PMID: 26091340 
 
“Nudix hydrolases degrade protein conjugated ADP-ribose” 
Casey M. Daniels, Puchong Thirawatananond, Shao-En Ong, Sandra B. Gabelli, Anthony K.L. 
Leung 
Manuscript in preparation 
 
“A phosphoproteomic approach to characterize mono- and poly(ADP-ribosyl)ation sites 
from cells” 
Casey M. Daniels, Shao-En Ong, Anthony K.L. Leung 
Journal of Proteome Research 2014 13 (8), 3510-3522  
PMID: 24920161 
 
PRESENTATIONS & PUBLISHED ABSTRACTS: 
2015 “Characterizing ADP-ribosylation sites by Mass Spectrometry” – poster 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 Annual Retreat – Department of Biochemistry & Molecular Biology 
 Johns Hopkins Bloomberg School of Public Health – Baltimore, MD 
 
2014 “Using Mass Spectrometry to Identify Sites of ADP-ribosylation” – poster  
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 PTMs in Cell Signaling – 6th Copenhagen Bioscience Conference, Denmark 
 
2014 “A phosphoproteomic approach to characterize mono- and poly(ADP-ribosyl)ation 
sites from whole cell lysate” – poster 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 MaxQuant Summer School, National Institutes of Health, Bethesda, MD 
 
2014 “A phosphoproteomic approach to characterize mono- and poly(ADP-ribosyl)ation 
sites from whole cell lysate” – poster 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 American Society for Mass Spectrometry (ASMS) Conference, Baltimore, MD 
 
2014 “A phosphoproteomic approach to characterize mono- and poly(ADP-ribosyl)ation 
sites from whole cell lysate” – poster 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 The PARP Family & Friends: Gene Regulation and Beyond, Cold Spring Harbor, 
NY 
 
2014 “Mass Spectrometry and ADP-ribosylation” – oral presentation 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 
 
 Annual Retreat – Department of Biochemistry & Molecular Biology 
 Johns Hopkins Bloomberg School of Public Health – Baltimore, MD 
 
2013 “Applying Mass Spectrometry to the Study of Poly(ADP-ribosyl)ation” – oral 
presentation 
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 Annual Retreat – Department of Biochemistry & Molecular Biology 
 Johns Hopkins Bloomberg School of Public Health – Baltimore, MD 
 
2012 “Using SILAC and Mass Spectrometry to identify targets of PARP-1” – poster  
 C.M. Daniels*, S.E. Ong, A.K.L Leung 
 Annual Retreat – Department of Biochemistry & Molecular Biology 
 Johns Hopkins Bloomberg School of Public Health – Baltimore, MD 
 
2009 “How Skin Ages: Exploring the Role of the Nuclear Receptor LXRβ in the Skin” – 
poster 
 C.M. Daniels*, Q. Shen, W. Wang, C.C. Thompson 
 Undergraduate Research and Creative Achievement Day 
 University of Maryland, Baltimore County – Baltimore, MD 
 
2008 “The Role of Thymidine Kinase and Thymidylate Synthase in the Response of 
Tumor Cells to the Suicide Prodrug 2’-F-ara-Deoxyuridine” – poster 
 P. Phatak*, C.M. Daniels, A.F. Shields, J.M. Collins, P.M. LoRusso, A.M. Burger 
 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - 
Geneva, Switzerland 
 Abstract published in the European Journal of Cancer: October 2008, 6(12), p. 
 150 
  
2008 “How Skin Ages: Exploring the Role of the Nuclear Receptor LXRβ in the Skin” – 
poster 
 C.M. Daniels*, Q. Shen, W. Wang, C.C. Thompson 
 Mid-Atlantic Pharmacology Society’s Annual Meeting - King of Prussia, PA 
 Abstract published in The Pharmacologist: December 2008, 50(4), pg 210 
 
2008 “The Role of Thymidine Kinase and Thymidylate Synthase in the Response of 
Tumor Cells to 2’-F-ara-deoxyuridine” – poster 
 C.M. Daniels*, P. Shelton, P. Phatak, C. Burgess ,K. Natharajan, P. LoRusso, A.M. Burger 
 UMBC’s Undergraduate Research and Creative Achievement Day – Baltimore, MD 
 
TRAINING COURSES: 
MaxQuant Summer School, National Institutes of Health, Bethesda, MD 
Proteomics Student, July 2014 
 
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 








Anthony K.L. Leung, PhD 
Assistant Professor, Department of Biochemistry & Molecular Biology 
Johns Hopkins Bloomberg School of Public Health 
410-502-8939, anleung@jhsph.edu 
 
Shao-En Ong, PhD 
Assistant Professor, Department of Pharmacology 
University of Washington 
206-616-6962, shaoen@uw.edu 
 
Pierre Coulombe, PhD 
Chair, Department of Biochemistry & Molecular Biology 








Site Directed Mutagenesis 
Agarose Gel Electrophoresis 
PCR amplification 
Protein Analysis 
Bacterial & Mammalian Cell Culture (SILAC, iTRAQ) 
Protein expression & purification 
Microscopy 
SDS Page and Western Blotting 
Fast Protein Liquid Chromatography (FPLC) 
Mass Spectrometry (MS1 and MS2) 
Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC) 
Synthetic Chemistry 





Nuclear Magnetic Resonance (NMR, 1H, 13C) 
High Pressure Liquid Chromatography (HPLC) 
Thin Layer Chromatography (TLC) 
 Data analysis and presentation (General) 
  Adobe Illustrator and Photoshop (Proficient) 
  Microsoft Excel, Word and PowerPoint (Proficient) 
  GraphPad Prism 
  R 
 Data analysis (Molecular Biology) 
  MultiGauge (Proficient) 
   Image Studio (Proficient) 
  ApE (Proficient) 
  UNICORN (Proficient) 
  ImageJ (Proficient) 
 Data analysis (Mass Spec and Proteomics) 
  MaxQuant (Proficient) 
  Protein Prospector (Proficient) 
  Thermo Xcalibur (Proficient) 
  Scaffold 
  Mascot 
  PEAKS 
  Skyline 
  Perseus 
